<SUBMISSION>
<ACCESSION-NUMBER>0000912057-01-513785
<TYPE>10-K/A
<PUBLIC-DOCUMENT-COUNT>5
<PERIOD>20001229
<FILING-DATE>20010509
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>STAAR SURGICAL COMPANY
<CIK>0000718937
<ASSIGNED-SIC>3851
<IRS-NUMBER>953797439
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>0101
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>10-K/A
<ACT>34
<FILE-NUMBER>000-11634
<FILM-NUMBER>1626054
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>1911 WALKER AVE
<CITY>MONROVIA
<STATE>CA
<ZIP>91016
<PHONE>8183037902
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>1911 WALKER AVE
<CITY>MONROVIA
<STATE>CA
<ZIP>91016
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>a2044612z10-ka.htm
<DESCRIPTION>10-K/A
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01WLA1211_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<HR NOSHADE>
<HR NOSHADE>
<P ALIGN="CENTER"><FONT SIZE=5><B>SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=2><B>WASHINGTON, D.C. 20549  </B></FONT></P>

<HR NOSHADE ALIGN="CENTER" WIDTH="120">
<P ALIGN="CENTER"><FONT SIZE=2><B> <A NAME="ba1211_form_10-k/a_amendment_no._1"> </A>
<A NAME="toc_ba1211_1"> </A>
<BR>    </B></FONT><FONT SIZE=5><B>FORM 10-K/A<BR>  </B></FONT><FONT SIZE=2><B>Amendment No.&nbsp;1    <BR>  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><BR><FONT SIZE=3>/x/</FONT></TD>
<TD WIDTH="88%"><BR><FONT SIZE=3><B>Annual</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2 ALIGN="CENTER"><BR><FONT SIZE=2><B>For the fiscal year ended December&nbsp;29, 2000</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><FONT SIZE=2><B><BR>
&nbsp;</B></FONT></TD>
<TD WIDTH="88%"><FONT SIZE=2><B><BR>
&nbsp;</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="12%" ALIGN="CENTER"><BR><FONT SIZE=3>/&nbsp;/</FONT></TD>
<TD WIDTH="88%"><BR><FONT SIZE=3><B>Transition Report Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2 ALIGN="CENTER" VALIGN="TOP"><BR><FONT SIZE=2><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2 ALIGN="CENTER"><FONT SIZE=2><B><BR>
Commission file number: 0-11634</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
<P ALIGN="CENTER"><FONT SIZE=5><B>STAAR SURGICAL COMPANY<BR>  </B></FONT><FONT SIZE=2>(Exact name of registrant as specified in its charter) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><BR><FONT SIZE=2><B>Delaware</B></FONT><FONT SIZE=2><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><BR><FONT SIZE=2><B>95-3797439</B></FONT><FONT SIZE=2><BR>
(I.R.S. Employer Identification No.)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="49%" ALIGN="CENTER"><BR><FONT SIZE=2><B>1911 Walker Avenue<BR>
Monrovia, California<BR> </B></FONT><FONT SIZE=2>(Address of principal executive offices)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="49%" ALIGN="CENTER"><FONT SIZE=2><BR>
<BR></FONT> <FONT SIZE=2><B>91016<BR> </B></FONT><FONT SIZE=2>(Zip Code)</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
<P ALIGN="CENTER"><FONT SIZE=2>(Registrant's telephone number, including area code):&nbsp;</FONT><FONT SIZE=2><B>(626)&nbsp;303-7902  </B></FONT></P>

<HR NOSHADE>
<HR NOSHADE>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="1",CHK=507622,FOLIO='blank',FILE='DISK022:[01WLA1.01WLA1211]BA1211A.;15',USER='DMALONE',CD=';8-MAY-2001;14:09' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="bb1211_explanatory_note"> </A>
<A NAME="toc_bb1211_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXPLANATORY NOTE    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;1 ("Amendment No.&nbsp;1") on Form&nbsp;10-K/A to the Company's Annual Report on Form&nbsp;10-K for the
fiscal year ended December&nbsp;29, 2000 amends the Form&nbsp;10-K by adding to it two exhibits included on the original Exhibit List but not included in the original filing (exhibits
10.20 and 10.32), correcting one exhibit (exhibit&nbsp;10.58), and adding exhibit number 10.77, which was unintentionally omitted. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="bb1211_signatures"> </A>
<A NAME="toc_bb1211_2"> </A>
<BR></FONT><FONT SIZE=2><B>SIGNATURES    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this amendment to its
Form&nbsp;10-K to be signed on its behalf by the undersigned, thereunto duly authorized on May&nbsp;8, 2001. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><B>STAAR SURGICAL COMPANY</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>DAVID BAILEY</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> David Bailey, </FONT><FONT SIZE=2><I>President and<BR>
Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=2,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="1",CHK=310089,FOLIO='blank',FILE='DISK022:[01WLA1.01WLA1211]BB1211A.;6',USER='DMALONE',CD=';8-MAY-2001;14:10' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01WLA1211_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ba1211_1">FORM 10-K/A Amendment No. 1</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_bb1211_1">EXPLANATORY NOTE</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_bb1211_2">SIGNATURES</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DMALONE,SEQ=,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>2
<FILENAME>a2044612zex-10_20.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01WLA1211_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ha1204_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ha1204_exhibit_10.20"> </A>
<A NAME="toc_ha1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.20    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_patent_license_agreement"> </A>
<A NAME="toc_ha1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>PATENT LICENSE AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Eye Microsurgery Intersectoral Research and Technology Complex, Moscow, Russia, represented by General Director Mr. Fedorov S.N., from here on referred to
as the "Licensor", and STAAR Surgical AG, a Swiss corporation, Hidau, Switzerland represented by Mr. Vladimir Feingold and Director Mr. John R. Wolf, from here on referred to as the "Licensee", taking
into account that the Licensor possesses the "Technology for Producing Collagen-Based Cross-Linked Drain", and the Licensee wants to acquired the license on this technology. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensor and Licensee agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_1"> </A>
<A NAME="toc_ha1204_3"> </A>
<BR></FONT><FONT SIZE=2><B>Article 1    <BR>  </B></FONT></P>

<P><FONT SIZE=2><B>DEFINITIONS:  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.0. For the purposed of this Agreement the following expressions have the meanings indicated below: </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.1.
"Product" is the product described in Appendix 1. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.2.
"Patent" is the patent whose detailed description is given in Appendix 2. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.3.
"Trade mark" is the trade mark registered by the Licensor and having parameters specified in Appendix 3. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.4.
"Technical knowledge" stands for technical information, khow-how, manufacturing technology, technical data, material specifications, and other information used by the Licensor
during the manufacture of the Product (or which is necessary and sufficient for the Licensee to make the Product according to the standard and quality of the product made by the Licensor) (including
any improvements obtained during the validity period of this Agreement). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.5.
"Territory" covers all countries listed in Appendix 4. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.6.
"Exclusive territory" covers the countries listed in part 1 of Appendix 4. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.7.
"Non-exclusive territory" covers the countries listed in part 2 of Appendix 4. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.8.
"Year" means any period of time of 12 months starting from the date of executing the Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_2"> </A>
<A NAME="toc_ha1204_4"> </A>
<BR></FONT><FONT SIZE=2><B>Article 2    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor is an owner of U.S. Patent No. 4,978,352 granted on December 18, 1990 and has the right of disposal of the said patent. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No
prior transfers occurred. No share or total property covered by the Patent have been transferred to any person except for the Licensee according to this Agreement. The Licensor's
rights are free from the right of detention, pledge, backing interest or other proprietary burdens. The Licensor disclosed no confidential information, production secrets or know-how relating to the
technical aspects of the patent to any third legal or physical person. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
the Licensor has production secrets and experience (know-how) concerning the subject matter of this license. For valuable consideration, the receipt and sufficient of
which are confirmed by the Licensee, the Licensor assigns to the Licensee its entire and exclusive right, title, interest, and material right relating to the "Patent" described in Appendix 2 to this
Agreement. The </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=344618,FOLIO='1',FILE='DISK032:[01WLA4.01WLA1204]HA1204A.;8',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_ha1204_1_2"> </A>
<BR>

<P><FONT SIZE=2>
Licensee shall acquire the entire and exclusive right belonging to the Licensor to the Licensee's benefit for the whole term of validity of the Patent. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_3_i._technical_field_of_application"> </A>
<A NAME="toc_ha1204_5"> </A>
<BR></FONT><FONT SIZE=2><B>Article 3<BR>  <BR>    I. Technical field of application    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The license for the "Technology for Producing Collagen-Based Cross-Linked Drains" relates to the entire sphere of application of the inventions mentioned in
the patents and listed in the preamble, as well as everything that definitively stems from these inventions. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Parties shall inform each other openly and without any reservations on the possible fields of application of the inventions, that were unknown to the Parties at the day of
conclusion of the Agreement, and, as proved later, can be carried by the Parties into effect and/or can be wanted for realization. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_ii._license_type"> </A>
<A NAME="toc_ha1204_6"> </A>
<BR></FONT><FONT SIZE=2><B>II. License type    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Patent deals with an exclusive license </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In
so doing, however, the Licensor keeps the right of manufacturing the products covered by the license, to use them or sell on a nonexclusive territory specified
in part 2 of Appendix 4. Furthermore, the Licensor reserves a right of realizing the product covered by the license in its branches and joint ventures, existing or to be created, on the exclusive
territory specified in part 1 of Appendix 4. This license is intended for manufacture, use and sale. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_4_territory_covered_by_the_agreement"> </A>
<A NAME="toc_ha1204_7"> </A>
<BR></FONT><FONT SIZE=2><B>Article 4<BR>  <BR>    Territory covered by the Agreement    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The license was granted for use on the exclusive territory (see Appendix 4). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee has the right of production in other countries including those where the Licensee has no protective rights. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee has the right to export the product to all countries except for those located on the non-exclusive territory. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee shall prevent export to the countries where such an export is prohibited. If, in spite of this, the export shall be effected, the Licensor shall have the right of
cancelling the Agreement by means of a simple written message. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee shall pay conventional penalty equal to 20-fold price of the export delivery, which is inadmissible by virtue of the above statements. In an equivalent manner the
Licensee shall put on its customers an obligation to avoid export of the subject matter of this license, because it is inadmissible according to the above statements, and to pay to it a conventional
penalty in an amount of 20-fold price of the exported goods in every case of infringement. This sum the Licensee shall transfer to the Licensor. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_5_licence_registration"> </A>
<A NAME="toc_ha1204_8"> </A>
<BR></FONT><FONT SIZE=2><B>Article 5<BR>  <BR>    Licence registration    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Party shall have the right of registering the license in the Patent Office provided that such registration is allowed by the legislation of the country or
countries with respect to which the license is given. The Licensor shall transfer to the Licensee the authority and approval. The registration fee shall be covered by the Licensee. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=170545,FOLIO='2',FILE='DISK032:[01WLA4.01WLA1204]HA1204B.;9',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_ha1204_1_3"> </A>
<BR>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_6_drawings_and_descriptive_documents"> </A>
<A NAME="toc_ha1204_9"> </A>
<BR></FONT><FONT SIZE=2><B>Article 6<BR>  <BR>    Drawings and descriptive documents    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor shall give to the Licensee all existing drawings, plans, quality inspection system, and other technical documents required for the manufacture
under license. These documents may be duplicated. The Licensee shall treat these drawings and documents as secret materials during the entire term of action of this Agreement and after it will be
expired. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_7_mastering"> </A>
<A NAME="toc_ha1204_10"> </A>
<BR></FONT><FONT SIZE=2><B>Article 7<BR>  <BR>    Mastering    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor is released from responsibility for the risks associated with the industrial-scale mastering of the manufacture under license, for which the
Licensee is responsible. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_responsibility_for_commercial_realization"> </A>
<A NAME="toc_ha1204_11"> </A>
<BR></FONT><FONT SIZE=2><B>Responsibility for commercial realization    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor is responsible for the commercial realization of the invention. The realization risk is taken solely by the Licensee. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_8_i._quality_of__ha102346"> </A>
<A NAME="toc_ha1204_12"> </A>
<BR></FONT><FONT SIZE=2><B>Article 8<BR>  <BR>    I. Quality of products manufactured under license    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensee shall manufacture the products under license whose quality is the same as those manufactured by Licensor. The Licensor provides all necessary
consultations and information accumulated from its own experience. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_ii._consequences_of_poor_quali__ii.02883"> </A>
<A NAME="toc_ha1204_13"> </A>
<BR></FONT><FONT SIZE=2><B>II. Consequences of poor quality of products manufactured under license    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor has the right of quality monitoring so as to check if the products manufactured under license correspond to the quality established by the
Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_iii._sublicenses"> </A>
<A NAME="toc_ha1204_14"> </A>
<BR></FONT><FONT SIZE=2><B>III. Sublicenses    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;The
Licensee has the right to offer sublicensee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;In
case of selling a sublicense the earning is distributed between the Licensor and Licensee of this Agreement in equal parts. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ha1204_article_9_confidentiality"> </A>
<A NAME="toc_ha1204_15"> </A>
<BR></FONT><FONT SIZE=2><B>Article 9<BR>  <BR>    Confidentiality    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Parties concluding this Agreement agree that they consider as secret all technical and technological information relating to the production under licence
and made available to the Licensee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
information obtained from the Licensor is kept in secret during the entire validity period of the Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee has the right to use free of charge the entire technical information after the validity period of this Agreement is expired. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
right of free use of the technical and technological information is given to the Licensee also during the effective period of this Agreement if such information and know-how have
become public. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=282687,FOLIO='3',FILE='DISK032:[01WLA4.01WLA1204]HA1204B.;9',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<BR>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_hc1204_1_4"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hc1204_exhibit_10.20"> </A>
<A NAME="toc_hc1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.20    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_10_improvements_and_am__art02466"> </A>
<A NAME="toc_hc1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>Article 10<BR>  <BR>    Improvements and amendments of the subject of license    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor is obliged to inform the Licensee about all modifications and improvements, that shall be made during the validity period of this Agreement and
concerning the subject matter of the license. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If
the improvements are protected by a patent, the Licensee shall get the protective rights for it. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If
the amendments and improvements shall lead to a patentable invention, it might be transferred to the Licensee free of charge with simultaneous prolongation of the period validity
under definite conditions. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_11_technical_assistance"> </A>
<A NAME="toc_hc1204_3"> </A>
<BR></FONT><FONT SIZE=2><B>Article 11<BR>  <BR>    Technical assistance    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensor submits to the Licensee scrupulously and unconditionally all technical assistance and necessary advisement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensor, at the expense of the Licensee, shall sent specialists under the following conditions: </FONT></P>

<UL>
<DL compact>
<DT><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
skill of the sent personnel must be sufficient for solving the technical problems that may arise with respect to the Agreement;
<BR><BR></FONT></DD><DT><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
period of working in the Licensee's country shall be agreed later;
<BR><BR></FONT></DD><DT><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
Licensee shall cover the expenses associated with the accommodation, transportation and insurance of the expatriate personnel. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee shall pay the personnel wages in US dollars in an amount twice the sum they have in their own country. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_12_amendments_and_impr__art02317"> </A>
<A NAME="toc_hc1204_4"> </A>
<BR></FONT><FONT SIZE=2><B>Article 12<BR>  <BR>    Amendments and improvements to be made by Licensee    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The amendments and improvements that shall be made by the Licensee with respect to the subject of the license may be made without special permission of the
Licensor. The Licensee has the right to perform the amendments and improvements without Licensor's permission provided that the Licensee alone shall be responsible for these amendments and
improvements. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_13_payments"> </A>
<A NAME="toc_hc1204_5"> </A>
<BR></FONT><FONT SIZE=2><B>Article 13<BR>  <BR>    Payments    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensee undertakes to pay within 10 days following the effective date of this Agreement and prior to the submission of the drawings and documents, the sum
of one hundred thousand US dollars (100,000 USD) as a single payment. The money is remitted to Russian "Vneshtorgbank" corresponding account No. 608-205-524 in the External Trade in the National
Republican Bank of New-York, USA, with an order to credit for the above sum account No. 67087105/001 of the Eye Microsurgery Intersectoral Research and Technology Complex in the "Vneshtorgbank"
(External Trade Bank of the Russian Federation), Moscow. The documentation shall be submitted to the Licensee only after the said sum has been received by the said bank. The Licensee shall have no
right to ask this sum back even if the Agreement is cancelled for any reason. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=4,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=335531,FOLIO='4',FILE='DISK032:[01WLA4.01WLA1204]HC1204A.;11',USER='TOSBORNA',CD=';4-MAY-2001;17:20' -->
<A NAME="page_hc1204_1_5"> </A>
<BR>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_14"> </A>
<A NAME="toc_hc1204_6"> </A>
<BR></FONT><FONT SIZE=2><B>Article 14    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;After receiving the registration documents to patent No. 4,978,352 from the US Patent Office, the Licensee shall pay to the Licensor seventy five thousand US
dollars (75,000 USD) within 10 days. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under
the payment according to Article 14 the Licensee shall give the Licensor a bank guarantee on fulfillment of its obligations on the payment for a sum of seventy five thousand US
dollars (75,000 USD) for a period of 3 months and within 10 days from the day of signing the contract. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_16_minimum_payments"> </A>
<A NAME="toc_hc1204_7"> </A>
<BR></FONT><FONT SIZE=2><B>Article 16<BR>  <BR>    Minimum payments    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Regardless of the scope of annual sales actually effected by the Licensee, the total volume of the annual license payments must not be lower than: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
1996 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
1997 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
1998 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
1999 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
2000 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
2001 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
2002 - fifty thousand US dollars (50,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in
2003 - seventy five thousand US dollars (75,000 USD) </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Term
of payment: 1st quarter of each year. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_17_royalty"> </A>
<A NAME="toc_hc1204_8"> </A>
<BR></FONT><FONT SIZE=2><B>Article 17<BR>  <BR>    Royalty    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the total Licensee's earnings from the sales exceeds 1,000,000 USD, by its wish and on an agreement with the Licensor, the Licensee, in addition to the
guaranteed minimum payments, may partially reimburse the license price from the sums paid by its buyers for the products made under license and delivered under conditions of free plant without
packing, as well as the sums obtained from learning the technology used in ophthalmosurgery with deduction of trade taxes: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Percentage
calculated on the basis of 12-month sales: six per cent (6.0%) from sales of up to 1,000,000 USD;<BR>
five and a half per cent (5.5%) from sales from 1,000,000 to 5,000,000 USD;<BR>
five per cent (5%) of sales from 5,000,000 to 10,000,000 USD;<BR>
four and a half per cent (4.5%) from sales above 10,000,000 USD. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;These
royalty sums are paid every quarter. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_18"> </A>
<A NAME="toc_hc1204_9"> </A>
<BR></FONT><FONT SIZE=2><B>Article 18    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the case of payment of royalty according to Article 17 with due account of the guaranteed payments according to Article 16, the payments to the Licensor are
made until a total sum of six hundred thousand US dollars ($600,000) is reached. Upon attaining this sum, all payments to the Licensor are stopped. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=5,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=25800,FOLIO='5',FILE='DISK032:[01WLA4.01WLA1204]HC1204A.;11',USER='TOSBORNA',CD=';4-MAY-2001;17:20' -->
<A NAME="page_hc1204_1_6"> </A>
<BR>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_19_appearance_o__hc102086"> </A>
<A NAME="toc_hc1204_10"> </A>
<BR></FONT><FONT SIZE=2><B>Article 19<BR>  <BR>    Appearance of the right for license payment    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The right for license payment arises as soon as the Licensee gets payment from the buyer. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_taxes_and_duties"> </A>
<A NAME="toc_hc1204_11"> </A>
<BR></FONT><FONT SIZE=2><B>Taxes and duties    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If direct sales taxes is taken in the Licensee's country, they are paid by the Licensee. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_20_accounting_and_reports"> </A>
<A NAME="toc_hc1204_12"> </A>
<BR></FONT><FONT SIZE=2><B>Article 20<BR>  <BR>    Accounting and reports    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensee is obliged to keep accounts in special books, in which it shall put the accurate number of the products manufactured under license according to
this Agreement, ordinal numbers applied onto the machines and all other data needed for calculation of the license price. The Licensor has the right to audit these books and their correspondence with
the general accounting of the Licensee through an auditor approved by the Licensee. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee shall bear the expenses associated with such an audit. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_21_calculation_on_license_payments"> </A>
<A NAME="toc_hc1204_13"> </A>
<BR></FONT><FONT SIZE=2><B>Article 21<BR>  <BR>    Calculation on license payments    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The calculations on the license payments are performed at the end of each calendar year. The Licensee shall send the complete data on these calculations within
a month following the day of their performance and to remit the calculated sum within the same period. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Licensee pays to the Licensor the money in the same currency, in which the Licensee's customer agrees to pay. If the Licensee exceeds a time limit for payment, the Licensor may
take annual interest of 6% within 60 days after each quarter. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_22_obligation_on_using__art03151"> </A>
<A NAME="toc_hc1204_14"> </A>
<BR></FONT><FONT SIZE=2><B>Article 22<BR>  <BR>    Obligation on using the license in production of competitive articles    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensee is obliged to use the license. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_23_patent_support"> </A>
<A NAME="toc_hc1204_15"> </A>
<BR></FONT><FONT SIZE=2><B>Article 23<BR>  <BR>    Patent support    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensee shall support the Patent that is put as a a base of this license Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_24_patent_rights_protection"> </A>
<A NAME="toc_hc1204_16"> </A>
<BR></FONT><FONT SIZE=2><B>Article 24<BR>  <BR>    Patent rights protection    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Patent is infringed by a third party and the Licensor becomes aware of such infringement, the Licensor shall promptly notify the Licensee in writing of
such infringement or unfair competition. The Licensee, in its sole discretion, shall determine if it shall defend the Patent against any such infringement or unfair competition. If the Licensee
determines that it shall defend the Patent infringement or unfair competition, it shall so notify the Licensor. The Licensor agrees to cooperate and assist in prosecution of any action in the nature
of unfair competition or patent infringement prosecuted by the Licensee. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=6,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=802997,FOLIO='6',FILE='DISK032:[01WLA4.01WLA1204]HC1204B.;8',USER='TOSBORNA',CD=';4-MAY-2001;17:20' -->
<A NAME="page_hc1204_1_7"> </A>
<BR>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;The Licensor shall support the Licensee, first of all, if such a support is provided by the property right of the respective country. The Licensor shall give the Licensee all
necessary authority and documents that shall enable the Licensee to bring a suit and to present witnesses or coauthors. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
party making a decision to suit the third party bears possible expenses in preparation and conduction of legal proceedings. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_25_licensee_s_obligati__art02323"> </A>
<A NAME="toc_hc1204_17"> </A>
<BR></FONT><FONT SIZE=2><B>Article 25<BR>  <BR>    Licensee's obligation to defence the patent rights    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Licensee commit itself that neither it personally nor its authorized person shall dispute the patent rights put in the base of this Agreement except the
cases, when these rights shall be no longer valid through the Licensor's fault. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_26_cancellation_of_pat__art02341"> </A>
<A NAME="toc_hc1204_18"> </A>
<BR></FONT><FONT SIZE=2><B>Article 26<BR>  <BR>    Cancellation of Patent: its effect on the Agreement    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the protective rights setting up the base of this Agreement are cancelled by the claim of a third party, the paid license payments in no case shall be
reimbursed, however, if the term of their payment does not yet come, they shall not be taken. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_27_agreement_validity"> </A>
<A NAME="toc_hc1204_19"> </A>
<BR></FONT><FONT SIZE=2><B>Article 27<BR>  <BR>    Agreement validity    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Agreement validity period is equal to that of the patent validity. The Agreement shall come into force from the moment of its signing. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_28_force_majeure"> </A>
<A NAME="toc_hc1204_20"> </A>
<BR></FONT><FONT SIZE=2><B>Article 28<BR>  <BR>    Force Majeure    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Either party is relieved from liability for partial or complete non-performance of their obligations under present Agreement in some circumstances that aroused
independent of their will. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
circumstances caused by events that were independent of the will of the parties of this Agreement so that the fair party could not avoid or eliminate, are considered as cases
releasing this party from its obligations, if they take place after signing the Agreement and prevent its fulfillment completely of partially. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
cases of unsurmountable force are reduced to the following events: war, military actions, revolts, mobilization, road accidents and natural disasters, legal acts of authorities
affecting the fulfillment of the obligations, and all other events which are considered as circumstances of unsurmountable force by a competent arbitration court. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hc1204_article_29_applicable_legislation"> </A>
<A NAME="toc_hc1204_21"> </A>
<BR></FONT><FONT SIZE=2><B>Article 29<BR>  <BR>    Applicable legislation    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is applicable to the Swiss Law. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=7,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=432051,FOLIO='7',FILE='DISK032:[01WLA4.01WLA1204]HC1204B.;8',USER='TOSBORNA',CD=';4-MAY-2001;17:20' -->
<BR>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_he1204_1_8"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="he1204_article_30_legal_protection_and_arbitration"> </A>
<A NAME="toc_he1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Article 30<BR>  <BR>    Legal protection and arbitration    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If any dispute or difference shall arise between the parties to this Agreement as to any matter or thing arising in connection with the Agreement then the
aggrieved party shall give to the other party a notice in writing setting out in full detailed particulars of the dispute or difference. Upon receipt of the notice the parties shall agree to appoint
the International Chamber of Commerce (Paris) as a mediator. International Chamber of Commerce shall appoint a date, time and venue (unless the parties agree to a date, time and venue) for mediation
proceedings to be held to discuss in detail the dispute or difference. The parties shall not be legally represented at the mediation proceedings but shall present, in their own manner, with the
assistance or witnesses and documentary evidence, the details of their respective cases. If, at the conclusion of the mediation proceedings the parties fail to resolve the dispute or difference,
either party may give to the other party, within 14 days, a notice stating that at the expiration of 30 days it will proceed to have the dispute of difference referred to a court of competent
jurisdiction in Switzerland (or another country as the parties agree) and at the expiration of such 30 days may so proceed. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="he1204_article_31_miscellaneous"> </A>
<A NAME="toc_he1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>Article 31<BR>  <BR>    Miscellaneous    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The headings of the articles of the Agreement are intended solely for the convenience of reference and are not intended to explain, modify, or place any
construction on any of the provisions of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement covers all agreed provisions and aspects of the License Agreement. It has no any additional promises or terms as a condition of execution of the License Agreement,
along with other terms except those stated above. All preliminary agreements, promises, negotiations or presentations, which are not included into this License Agreement shall not be valid from the
moment of its signing. Any subsequent agreement, which shall lead to a change or cancellation of this License Agreement, shall be valid solely if it is made in writing and signed by the authorized
representatives of both parties. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="he1204_successors_and_assigns"> </A>
<A NAME="toc_he1204_3"> </A>
<BR></FONT><FONT SIZE=2><B>Successors and Assigns    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This Agreement and all of its provisions shall be binding and inure to the benefit of the successors and assigns of the parties. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If
not stated specially in this Agreement, all requested notices, requirements, questions, agreed statements, approvals, or other communications between the partners shall be made in
writing and delivered: (A)&nbsp;by a messenger (such a message is delivered personally), (B)&nbsp;by telegraph or air express mail (in so doing the messaged are sent by R-mail,
(C)&nbsp;electronic mail, fax or telephone provided that the recipient has a compatible device or confirms the receipt of the message (in this case it is assumed that the transmission or reception
of the message will be confirmed), or (D)&nbsp;by mailing a registered or valuable letter (in this case it is assumed that the letter shall be delivered at the 14th day after dispatching). The
messaged are sent to the following addresses: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Licensee&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;STAAR
Surgical AG<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hauptstrasse 104<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CH 2560 Hidau<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Switzerland<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Att: President<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A copy to address:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;STAAR Surgical Company<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1811 Walker Avenue<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Monrovia, California 91016<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Att: President&#151;Chief Executive Officer </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Licensor:&nbsp;&nbsp;&nbsp;&nbsp;Eye
Microsurgery Intersectoral Research and Technology Complex, Moscow, Russia </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
above addresses may be changed by notifying the other party about this action as mentioned above. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=8,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=926701,FOLIO='8',FILE='DISK032:[01WLA4.01WLA1204]HE1204A.;15',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_he1204_1_9"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="he1204_the_right_of_signing_the_document"> </A>
<A NAME="toc_he1204_4"> </A>
<BR></FONT><FONT SIZE=2><B>The right of signing the document    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each party states that it has all necessary authority to sign this License Agreement. All individual signings of this Agreement for the party that is a
corporation, company or another legal counsel, or a signature of a proxy or another authorized person, is accompanied by confirmation of the fact that this
person has the right of putting his signature under the given document on behalf of a respective organization or its manager. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This
License Agreement is concluded in two authentic copies, two of which are in English and two in Russian. The parties are agreed that the texts are identical and are an integral
part of the Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each
party of the Agreement shall be given two copies of this Agreement: one copy in English and one copy in Russian. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the parties thereto have executed this Assignment Agreement on the day and year set forth opposite their respective signatures below: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>"Licensor"</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2>EYE MICROSURGERY INTERSECTORAL</FONT><FONT SIZE=2><BR>
Research and Technology Complex</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>S. N. FEDOROV</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> S. N. Fedorov<BR></FONT> <FONT SIZE=2><I>General Director, academician</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
"Licensee"</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2>STAAR SURGICAL AG</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Vladimir Feingold, </FONT><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
By</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> John R. Wolf, </FONT><FONT SIZE=2><I>Director</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=9,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=444106,FOLIO='9',FILE='DISK032:[01WLA4.01WLA1204]HE1204A.;15',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_hf1204_1_10"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hf1204_appendix_1"> </A>
<A NAME="toc_hf1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Appendix 1    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hf1204_product_manufactured_under_license"> </A>
<A NAME="toc_hf1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>Product manufactured under license    <BR>  </B></FONT></P>

<DL compact>
<DT><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Name:&nbsp;&nbsp;Collagen-based
cross-linked drain
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Purpose
and field of application: </FONT></DD></DL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A
significant progress has presently been made in curing glaucoma with the help of the above drains. Well known in the art are non-penetrating operations, particularly with open-angle
glaucoma. This intervention is based on the idea of reducing the opthalmotonous pressure by guaranteed improvement of the conditions off draining the bulbi camera aqueous humor. This principle is met
by the collagen-based cross-linked drain. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
principal advantage of this article is high filtering capacity so that it can be used successfully for treatment of children and adults. The use of the collagen-based cross-linked
drain for treating 10,000 patients in the Eye Microsurgery Intersectoral Research and Technology Complex have shown that the opthalmotonous pressure has been reduced in 96% at the I&nbsp;stage of
illness, in 92% at the II&nbsp;stage of illness and 86% at the III&nbsp;stage of illness. The remote result of the treatment obtained during 9&nbsp;years have confirmed the stable effect and
high filtering capacity of the drain. </FONT></P>

<DL compact>
<DT><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>Technical
characteristics: </FONT></DD></DL>
<BR>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE WIDTH="66%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="15%" VALIGN="TOP"><FONT SIZE=2>Article size:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP"><FONT SIZE=2>length</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="67%"><FONT SIZE=2>3.0 x 3.5 mm</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="15%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="12%" VALIGN="TOP"><FONT SIZE=2>diameter</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="67%"><FONT SIZE=2>1.0 x 95 mm</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><BR>
Breaking strength:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="67%"><FONT SIZE=2><BR>
25 10<SUP>5</SUP></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><BR>
Density in swollen equilibrium state:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="67%"><FONT SIZE=2><BR>
1.001 d/cm<SUP>3</SUP></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><BR>
Content of heavy metal salts:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="67%"><FONT SIZE=2><BR>
less than 0.001%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><BR>
Article sterilization:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="67%"><FONT SIZE=2><BR>
radiation 2.5 mrad</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=10,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=899353,FOLIO='10',FILE='DISK032:[01WLA4.01WLA1204]HF1204A.;11',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_hh1204_1_11"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hh1204_appendix_2"> </A>
<A NAME="toc_hh1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Appendix&nbsp;2    <BR>  </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hh1204_exhibit_10.20"> </A>
<A NAME="toc_hh1204_2"> </A></FONT> <FONT SIZE=2><B>Exhibit 10.20    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Patent
granted to "Eye Microsurgery Intersectoral Research and Technology Complex" </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="80%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="3%" ALIGN="CENTER"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="16%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="76%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>1.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>U.S. Patent No.&nbsp;4,978,352<BR>
Priority of May&nbsp;23, 1989</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Patent owner:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>"Eye Microsurgery Intersectoral Research and Technology Complex"</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Inventors:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>S.N.&nbsp;Fedorov, S.N.&nbsp;Bagrov, V.T.&nbsp;Trofimov, T.S.&nbsp;Amstislavskaya, A.V.&nbsp;Osipov</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>PROCESS FOR PRODUCING COLLAGEN-BASED CROSS-LINKED BIOPOLYMER, AN IMPLANT FROM SAID BIOPOLYMER, METHOD FOR PRODUCING SAID IMPLANT, AND METHOD FOR HERMETIZATION OF CORNEAL OR SCLERAL WOUNDS INVOLVED IN EYE INJURIES, USING
SAID IMPLANT</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Future inventions</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
2.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Patent application in Russia No.&nbsp;95,104,576<BR>
Priority of April&nbsp;6, 1995.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Patent owner:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>"Eye Microsurgery Intersectoral Research and Technology Complex"</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Inventors:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>S.N.&nbsp;Fedorov, S.N.&nbsp;Bagrov, E.V.&nbsp;Larionov, A.F.&nbsp;Panasyuk</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>Method of Producing Material for Drain</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
3.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Patent application in Russia No.&nbsp;95,104,577<BR>
Priority of April&nbsp;6, 1995.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Patent owner:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>"Eye Microsurgery Intersectoral Research and Technology Complex"</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Inventors:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>S.N.&nbsp;Fedorov, S.N.&nbsp;Bagrov, E.V.&nbsp;Larionov</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="16%"><FONT SIZE=2>Title:</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>Method of Producing Bio-material to be used in Ophthalmology</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=11,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=115457,FOLIO='11',FILE='DISK032:[01WLA4.01WLA1204]HH1204A.;11',USER='TOSBORNA',CD=';4-MAY-2001;17:21' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_hj1204_1_12"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hj1204_appendix_3"> </A>
<A NAME="toc_hj1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Appendix 3    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Trade
marks of "Eye Microsurgery Intersectoral Research and Technology Complex </FONT></P>

<DL compact>
<DT><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Graphic
trade mark in the USA.<BR>
Certificate No.&nbsp;1.485.586, class&nbsp;41.
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Graphic
trade mark in the USA.<BR>
Certificate No.&nbsp;1.298.658, class&nbsp;10. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=12,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=228535,FOLIO='12',FILE='DISK032:[01WLA4.01WLA1204]HJ1204A.;5',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hj1204_1_13"> </A>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hj1204_appendix_4"> </A>
<A NAME="toc_hj1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>Appendix 4    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Territory
of validity of the Agreement </FONT></P>

<DL compact>
<DT><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Exclusive
territory,<BR>
USA, European countries, Latin America, Africa, Asia, Japan.
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Non-exclusive
territory,<BR>
Russia, CIS countries, Baltic Republics, China. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=13,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2",CHK=285788,FOLIO='13',FILE='DISK032:[01WLA4.01WLA1204]HJ1204B.;4',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01WLA1211_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ha1204_1">Exhibit 10.20</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_2">PATENT LICENSE AGREEMENT</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_3">Article 1</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_4">Article 2</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_5">Article 3 I. Technical field of application</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_6">II. License type</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_7">Article 4 Territory covered by the Agreement</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_8">Article 5 Licence registration</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_9">Article 6 Drawings and descriptive documents</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_10">Article 7 Mastering</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_11">Responsibility for commercial realization</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_12">Article 8 I. Quality of products manufactured under license</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_13">II. Consequences of poor quality of products manufactured under license</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_14">III. Sublicenses</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ha1204_15">Article 9 Confidentiality</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_hc1204_1">Exhibit 10.20</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_2">Article 10 Improvements and amendments of the subject of license</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_3">Article 11 Technical assistance</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_4">Article 12 Amendments and improvements to be made by Licensee</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_5">Article 13 Payments</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_6">Article 14</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_7">Article 16 Minimum payments</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_8">Article 17 Royalty</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_9">Article 18</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_10">Article 19 Appearance of the right for license payment</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_11">Taxes and duties</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_12">Article 20 Accounting and reports</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_13">Article 21 Calculation on license payments</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_14">Article 22 Obligation on using the license in production of competitive articles</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_15">Article 23 Patent support</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_16">Article 24 Patent rights protection</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_17">Article 25 Licensee's obligation to defence the patent rights</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_18">Article 26 Cancellation of Patent: its effect on the Agreement</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_19">Article 27 Agreement validity</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_20">Article 28 Force Majeure</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hc1204_21">Article 29 Applicable legislation</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_he1204_1">Article 30 Legal protection and arbitration</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_he1204_2">Article 31 Miscellaneous</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_he1204_3">Successors and Assigns</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_he1204_4">The right of signing the document</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_hf1204_1">Appendix 1</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hf1204_2">Product manufactured under license</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_hh1204_1">Appendix 2</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hh1204_2">Exhibit 10.20</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_hj1204_1">Appendix 3</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hj1204_2">Appendix 4</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DMALONE,SEQ=,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>3
<FILENAME>a2044612zex-10_32.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01WLA1211_3">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_hl1204_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hl1204_exhibit_10.32"> </A>
<A NAME="toc_hl1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.32    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hl1204_employment_agreement"> </A>
<A NAME="toc_hl1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>EMPLOYMENT AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This EMPLOYMENT AGREEMENT ("Agreement"), which is dated as of April 28, 1999, is made by and between STAAR SURGICAL COMPANY, a Delaware corporation, located at
1911 Walker Avenue, Monrovia, California, 91016 and hereinafter referred to as "Company", and JOHN SANTOS, whose address is 27850 Mount Rainier Way, Yorba Linda, California 92687, hereinafter referred
to as "Employee", based upon the following: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hl1204_recitals"> </A>
<A NAME="toc_hl1204_3"> </A>
<BR></FONT><FONT SIZE=2><B><I>RECITALS</I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Employee has been rendering services to Company as its Vice President Controller. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Company wishes to continue to retain the services of Employee as its Vice President Controller and to set forth in this
Agreement the duties and responsibilities Employee has agreed to undertake on behalf of Company; and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Employee wishes to continue to render services to Company as its Vice President Controller and to have set forth in this
Agreement the duties and responsibilities he has agreed to undertake on behalf of Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>WHEREAS,</B></FONT><FONT SIZE=2> Company and Employee intend that this Agreement will supercede and replace any and all other employment agreements or
arrangements for employment entered into by and between Company and Employee and that, upon execution of this Agreement, any such employment agreements or arrangements shall have no further force or
effect. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>THEREFORE,</B></FONT><FONT SIZE=2> in consideration of the foregoing and of the mutual promises contained in this Agreement, Company and Employee (who are
sometimes individually referred to as a "party" and collectively referred to as the "parties") agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hl1204_agreement"> </A>
<A NAME="toc_hl1204_4"> </A>
<BR></FONT><FONT SIZE=2><B><I>AGREEMENT</I></B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>1.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;SPECIFIED PERIOD.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the terms of this Agreement, Company hereby employs Employee and Employee hereby accepts employment with Company for a period which shall begin on the date of execution of
this Agreement and shall end three (3) years after that date. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject
to sections 10 and 11, this Agreement will be automatically renewed after its expiration unless either party gives notice to the other, at least sixty (60) days prior to the
expiration of the term, that the party desires to renegotiate this Agreement. Thereafter, the terms and conditions of this Agreement shall apply until the parties reach an agreement modifying them. If
an agreement is not reduced to writing and executed by the parties within sixty (60) days of the end of the specified period, then this Agreement shall continue on a month to month basis until
terminated by written notice given by either party at least thirty (30) days prior to the end of any monthly period. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>2.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;GENERAL DUTIES.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Employee
shall report to Company's Vice President, Chief Financial Officer or to his designee. Employee shall devote his entire productive time, ability, and attention to Company's
business during the term of this Agreement. In his capacity as Assistant Vice President Controller, Employee shall do and perform all services, acts, or things necessary or advisable to discharge his
duties under this Agreement, including, but not limited to, those duties and responsibilities included in the Position Description attached to this Agreement as Exhibit "A" and made a part of it.
Employee shall perform </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=348730,FOLIO='1',FILE='DISK032:[01WLA4.01WLA1204]HL1204A.;14',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hl1204_1_2"> </A>
<BR>

<P><FONT SIZE=2>
such other duties as are commonly performed by an employee of his rank in a publicly traded corporation or which may, from time to time, be prescribed by the Company through its Board of Directors
(the "Board") or its officers. Furthermore, Employee agrees to cooperate with and work to the best of his ability with Company's management team, which includes the Board and the officers and other
employees, to continually improve Company's reputation in its industry for quality products and performance. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>3.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;NONCOMPETITION, NONSOLICITATION AND NONINTERFERENCE AND PROPRIETARY PROPERTY AND
CONFIDENTIAL INFORMATION PROVISIONS.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)&nbsp;</B></FONT><FONT SIZE=2><B><I>Noncompetition.</I></B></FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;</FONT><FONT
SIZE=2><I>"Applicable Definitions"</I></FONT><FONT SIZE=2>&nbsp;&nbsp;For purposes of this section 3, the following capitalized terms shall have
the definitions set forth below: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.&nbsp;</FONT><FONT
SIZE=2><I>"Business Segments"</I></FONT><FONT SIZE=2>&#151;The term "Business Segments" is defined as each of Company's (or Company's
affiliates') products or product lines. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.&nbsp;</FONT><FONT
SIZE=2><I>"Competitive Business"</I></FONT><FONT SIZE=2>&#151;The term "Competitive Business" is defined as any business that is or may be
competitive with or similar to or adverse to any of Company's (or Company's affiliates') Business Segments, whether such business is conducted by a proprietorship, partnership, corporation or other
entity or venture. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.&nbsp;</FONT><FONT
SIZE=2><I>"Territory"</I></FONT><FONT SIZE=2>&#151;The term "Territory" is defined as the geographic area (both within the United States and
internationally) in which each Business Segment is carried on including, by way of example and not limitation, the entire geographic area in which Company conducts various phases of such Business
Segment, including purchasing, production, distribution, promotional and marketing activities, sales, and location of plants and warehouses. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;</FONT><FONT
SIZE=2><I>Covenant Not To Compete.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee hereby covenants and agrees that during the term of this
Agreement, and for a period of one (1) year from the date this Agreement is terminated or expires, Employee shall not, with respect to each Business Segment and within the boundaries of the Territory
applicable to such Business Segment without the prior written consent of Company (which consent may be withheld in the sole and absolute discretion of Company), directly or indirectly, either alone or
in association or in connection with or on behalf of any person, firm, partnership, corporation or other entity or venture now existing or hereafter created: (i) be or become interested or engaged in,
directly or indirectly, with any Competitive Business including, without limitation, being or becoming an organizer, investor, lender, partner, joint venturer, stockholder, officer, director,
employee, manager, independent sales representative, associate, consultant, agent, supplier, vendor, vendee, lessor, or lessee to any Competitive Business, or (ii) in any manner associate with, or aid
or abet or give information or financial assistance to any Competitive Business, or (iii) use or permit the use of Employee's name or any part thereof to be used or employed in connection with any
Competitive Business (collectively and severally, the "</FONT><FONT SIZE=2><I>Noncompetition Covenants</I></FONT><FONT SIZE=2>"). Notwithstanding the foregoing, the provisions of this section 3(a)2.
shall not be deemed to prevent the purchase or ownership by Employee as a passive investment of the outstanding capital shares of any publicly held corporation, so long as any other obligation or duty
under the Noncompetition Covenants are not breached. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;</FONT><FONT
SIZE=2><I>Separate Covenants.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The Noncompetition Covenants shall be construed to be divided into separate and
distinct Noncompetition Covenants with respect to (i) each Business Segment and (ii) each matter or type of conduct described therein. Each of such divided Noncompetition Covenants shall be separate
and distinct from all such other Noncompetition Covenants with respect to the same or any other Business Segment. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=924147,FOLIO='2',FILE='DISK032:[01WLA4.01WLA1204]HL1204B.;9',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hl1204_1_3"> </A>
<UL>
<BR>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;</FONT><FONT SIZE=2><I>Acknowledgements.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee acknowledges that: (i) the covenants and the restrictions contained in
the Noncompetition Covenants are necessary, fundamental, and required for the protection of Company's business; (ii) the Noncompetition Covenants relate to matters which are of a special, unique and
extraordinary value; and (iii) a breach of any of the Noncompetition Covenants will result in irreparable harm and damages which cannot be adequately compensated by a monetary award. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;</FONT><FONT
SIZE=2><I>Judicial Limitation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Notwithstanding the foregoing, if at any time a court of competent jurisdiction
holds that any portion of any Noncompetition Covenant is unenforceable by reason of its extending for too great a period of time or over too great a geographical area or by reason of its being too
extensive in any other respect, such Noncompetition Covenant shall be interpreted to extend only over the maximum period of time, maximum geographical area, or maximum extent in all other respects, as
the case may be, as to which it may be enforceable, all as determined by such court in such action. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)&nbsp;</B></FONT><FONT SIZE=2><B><I>Nonsolicitation and Noninterference.</I></B></FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;</FONT><FONT
SIZE=2><I>Covenants.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee hereby covenants and agrees that during the term of this Agreement, and for a
period of one (1) year from the date this Agreement terminates or expires, Employee shall not, either for Emplyee's own account or directly or indirectly in conjunction with or on behalf of any
person, partnership, corporation or other entity or venture: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.&nbsp;Solicit
or employ or attempt to solicit or employ any person who is then or has, within twelve (12) months prior thereto, been an officer, partner, manager, agent or
employee of Company or any affiliate of Company whether or not such a person would commit a breach of that person's contract of employment with Company or any affiliate of Company, if any, by reason
of leaving the service of Company or any affiliate of Company (the "</FONT><FONT SIZE=2><I>Nonsolicitation Covenant</I></FONT><FONT SIZE=2>"); or </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.&nbsp;On
behalf of, directly or indirectly, any Competitive Business (as such term is defined in section 3(a)1.ii.), or for the purpose of or with the reasonably
foreseeable effect of harming the business of Company, solicit the business of any person, firm or company which is then, or has been at any time during the preceding twelve (12) months prior to such
solicitation, a customer, client, contractor, supplier or vendor of Company or any affiliate of Company (the "</FONT><FONT SIZE=2><I>Noninterference Covenant</I></FONT><FONT SIZE=2>"). </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;</FONT><FONT
SIZE=2><I>Acknowledgements.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Each of the parties acknowledges that: (i) the covenants and the restrictions
contained in the Nonsolicitation and Noninterference Covenants are necessary, fundamental, and required for the protection of the business of Company; (ii) such Covenants relate to matters which are
of a special, unique and extraordinary value; and (iii) a breach of either of such Covenants will result in irreparable harm and damages which cannot be adequately compensated by monetary award. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;</FONT><FONT
SIZE=2><I>Judicial Limitation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Notwithstanding the foregoing, if at any time, despite the express agreement of
Company and Employee, a court of competent jurisdiction holds that any portion of any Nonsolicitation or Noninterference Covenant is unenforceable by reason of its extending for too great a period of
time or by reason of its being too extensive in any other respect, such Covenant shall be interpreted to extend only over the maximum period of time or to the maximum extent in all other respects, as
the case may be, as to which it may be enforceable, all as determined by such court in such action. </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=654061,FOLIO='3',FILE='DISK032:[01WLA4.01WLA1204]HL1204B.;9',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<UL>
<BR>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_hn1204_1_4"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(c)&nbsp;</B></FONT><FONT SIZE=2><B><I>Proprietary Property: Confidential Information.</I></B></FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;</FONT><FONT
SIZE=2><I>"Applicable Definitions"</I></FONT><FONT SIZE=2>&nbsp;&nbsp;For purposes of this section 3(c), the following capitalized terms shall
have the definitions set forth below: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.&nbsp;"</FONT><FONT
SIZE=2><I>Confidental Information</I></FONT><FONT SIZE=2>"&#151;The term "Confidential Information" is collectively and severally defined as
any information, matter or thing of a secret, confidential or private nature, whether or not so labeled, which is connected with Company's business or methods of operation or concerning any of
Company's suppliers, customers, licensors, licensees or others with whom Company has a business relationship, and which has current or potential value to Company or the unauthorized disclosure of
which could be detrimental to Company. Confidential Information shall be broadly defined and shall include, by way of example and not limitation: (i) matters of a business nature available only to
management and owners of Company of which Employee may become aware (such as information concerning customers, vendors and suppliers, including their names, addresses, credit or financial status,
buying or selling habits, practices, requirements, and any arrangements or contracts that Company may have with such parties. Company's marketing methods, plans and strategies, the costs of materials,
the prices Company obtains or has obtained or at which Company sells or has sold its products or services, Company's manufacturing and sales costs, the amount of compensation paid to employees of
Company and other terms of their employment, financial information such as financial statements, budgets and projections, and the terms of any contracts or agreements Company has entered into) and
(ii) matters of a technical nature (such as product information, trade secrets, know-how, formulae, innovations, inventions, devices, discoveries, techniques, formats, processes, methods,
specifications, designs, patterns, schematics, data, compilation of information, test results, and research and development projects). For purposes of the foregoing, the term "trade secrets" shall
mean the broadest and most inclusive interpretation of trade secrets as defined by Section 3426.1(d) of the </FONT><FONT SIZE=2><I>California Civil Code</I></FONT><FONT SIZE=2> (the Uniform Trade
Secrets Act) and cases interpreting the scope of said Section. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.&nbsp;</FONT><FONT
SIZE=2><I>"Proprietary Property"</I></FONT><FONT SIZE=2>&#151;The term "Proprietary Property" is collectively and severally defined as any
written or tangible property owned or used by Company in connection with Company's business, whether or not such property also qualifies as Confidential Information. Proprietary Property shall be
broadly defined and shall include, by way of example and not limitation, products, samples, equipment, files, lists, books, notebooks, records, documents, memoranda, reports, patterns, schematics,
compilations, designs, drawings, data, test results, contracts, agreements, literature, correspondence, spread sheets, computer programs and software, computer print outs, other written and graphic
records, and the like, whether originals, copies, duplicates or summaries thereof, affecting or relating to the business of Company, financial statements, budgets, projections, invoices. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;</FONT><FONT
SIZE=2><I>Ownership of Proprietary Property.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee acknowledges that all Proprietary Property which
Employee may prepare, use, observe, come into possession of and/or control shall, at all times, remain
the sole and exclusive property of Company. Employee shall, upon demand by Company at any time, or upon the cessation of Employee's employment, irrespective of the time, manner, cause or lack of cause
of such cessation, immediately deliver to Company or its designated agent, in good condition, ordinary wear and tear and damage by any cause beyond the reasonable control of Employee excepted, all
items of the Proprietary Property which are or have been in Employee's possession or under his control, as well as a statement describing the disposition of all items of the Proprietary Property
beyond Employee's possession or control in the event Employee has not previously returned such items of the Proprietary Property to Company. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;</FONT><FONT
SIZE=2><I>Agreement Not to Use or Divulge Confidential Information.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee agrees that he will not, in any
fashion, form or manner, unless specifically consented to in writing by Company, either </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=4,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=226076,FOLIO='4',FILE='DISK032:[01WLA4.01WLA1204]HN1204A.;12',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hn1204_1_5"> </A>
<UL>
<BR>

<P><FONT SIZE=2>
directly or indirectly use, divulge, transmit or otherwise disclose or cause to be used, divulged, transmitted or otherwise disclosed to any person, firm or corporation, in any manner whatsoever
(other than in Employee's performance of duties for Company or except as required by law) any Confidential Information of any kind, nature or description. The foregoing provisions shall not be
construed to prevent Employee from making use of or disclosing information which is in the public domain through no fault of Employee, provided, however, specific information shall not be deemed to be
in the public domain merely because it is encompassed by some general information that is published or in the public domain or in Employee's possession prior to Employee's employment with Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;</FONT><FONT
SIZE=2><I>Acknowledgement of Secrecy.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee acknowledges that the Confidential Information is not generally
known to the public or to other persons who can obtain economic value from its disclosure or use and that the Confidential Information derives independent economic value thereby, and Employee agrees
that he shall take all efforts reasonably necessary to maintain the secrecy and confidentiality of the Confidential Information and to otherwise comply with the terms of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;</FONT><FONT
SIZE=2><I>Inventions, Discoveries.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee acknowledges that any inventions, discoveries or trade secrets,
whether patentable or not, made or found by Employee in the scope of his employment with Company constitute property of Company and that any rights therein now held or hereafter acquired by Employee
individually or in any capacity are hereby transferred and assigned to Company, and agrees to execute and deliver any confirmatory assignments, documents or instruments of any nature necessary to
carry out the intent of this section when requested by Company without further compensation therefor, whether or not Employee is at the time employed by Company. Provided, however, notwithstanding the
foregoing, Employee shall not be required to assign his rights in any invention which qualifies fully under the provisions of Section&nbsp;2870(a) of the </FONT><FONT SIZE=2><I>California Labor
Code,</I></FONT><FONT SIZE=2> which provides, in pertinent part, that the requirement to assign "shall not apply to any invention that the employee developed entirely on his or her own time without
using employer's equipment, supplies, facilities or trade secret information except for those inventions that either: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Relate
at the time of conception or reduction to practice of the invention to the employer's business, or actual or demonstrably anticipated research or development
of the employer; or </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;Result
from any work performed by the employee for the employer." </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Employee
understands the he bears the full burden of proving to Company that an invention qualifies fully under Section&nbsp;2870(a). By signing this Agreement, Employee
acknowledges receipt of a copy of this Agreement and of written notification of the provisions of Section&nbsp;2870. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>4.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;COMPLIANCE WITH SECURITIES LAWS.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee
acknowledges that Company and Employee will be subject to the provisions of Section&nbsp;10(b), 16(a) and 16(b) of the Securities Exchange Act of 1934. Employee acknowledges that
Section&nbsp;16(a) of the Securities Exchange Act may require Employee to report the ownership or transfer of his stock or other securities in Company to the Securities and Exchange Commission and
that Sections&nbsp;10(b) and 16(b) can prohibit Employee from selling or transferring his stock or securities in Company. Employee agrees that he will comply with Company's policies, as stated from
time to time, relating to selling or transferring his stock or securities in Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>5.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;COMPENSATION.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)&nbsp;</B></FONT><FONT SIZE=2><B><I>Salary.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;During the term of this Agreement, Company shall pay to Employee a
base salary of One Hundred Twenty Five Thousand Dollars ($125,000.00) per year. Employee's annual salary shall be </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=5,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=818353,FOLIO='5',FILE='DISK032:[01WLA4.01WLA1204]HN1204A.;12',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hn1204_1_6"> </A>
<BR>

<P><FONT SIZE=2>
reviewed periodically by Company for the purpose of determining whether Employee's salary shall be increased. In no event shall this review take place less frequently than annually. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)&nbsp;</B></FONT><FONT SIZE=2><B><I>Employee Benefit Plans.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee shall be entitled, during the specified
period of this Agreement, to participate in any retirement, pension, profit-sharing, insurance, or other plans which may now be in effect or which may be adopted by Company. During the specified
period of this Agreement, Company, at its sole cost and expense, shall provide to Employee (i)&nbsp;medical and dental insurance through any insurer of Company's choice; (ii) term life insurance in
a face amount of $300,000.00 and; disability insurance as provided to other key executives. The benefit plans shall be with such underwriters and shall contain such provisions as Company, in its sole
discretion, may determine from time to time. Company may delete coverages and otherwise amend and change the type and quantity of insurance coverage it provides in its sole discretion. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)&nbsp;</B></FONT><FONT SIZE=2><B><I>Stock Options.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee shall be included in the 1998 STAAR Surgical Company
Stock Plan (the "Plan") adopted by Company. Pursuant to the terms of the Plan, Employee shall be entitled to purchase twenty-five thousand (25,000) shares of Company's common stock, which options
shall vest over a period of three (3)&nbsp;years, eight thousand, three hundred and thirty-three (8,333) shares each on
June&nbsp;16, 2000, June&nbsp;16, 2001 and June&nbsp;16, 2002. The purchase price per share shall be $10.63. Stock issued pursuant to the Plan shall be restricted stock, although Company shall
reserve the right to issue registered shares if it so decides. Executive agrees to be bound by the terms of the Plan as adopted. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>6.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;REIMBURSEMENT OF BUSINESS EXPENSES.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)&nbsp;</B></FONT><FONT SIZE=2><B><I>Reimbursement for Ordinary Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Company shall promptly reimburse
Employee for all reasonable business expenses incurred by Employee in connection with the business of Company. However, each such expenditure shall be reimbursable only if Employee furnishes to
Company adequate records and other documentary evidence required by federal and state statutes and regulations issued by the appropriate taxing authorities for the substantiation of each such
expenditure as an income tax deduction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)&nbsp;</B></FONT><FONT SIZE=2><B><I>Reimbursement for Extraordinary Expenses.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Any single business expense with a
cost in excess of One Thousand Dollars ($1,000) shall be deemed to be an extraordinary business expense. Employee shall not incur any extraordinary business expense unless the expense has been
approved by the Chief Executive Officer. If Employee fails to obtain the approval of the Chief Executive Officer, Company may refuse to reimburse Employee for that expense. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>7.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;ANNUAL VACATION/SICK LEAVE.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Employee
shall be entitled to at least three (3) weeks vacation time each year without loss of compensation. Employee shall be entitled to sick leave in accordance with Company's
general policy for its employees. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>8.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;INDEMNIFICATION OF LOSSES.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;So
long as Employee's actions were taken in good faith and in furtherance of Company's business and within the scope of Employee's duties and authority, Company shall indemnify and
hold Employee harmless to the full extent of the law from any and all claims, losses and expenses sustained by Employee as a result of any action taken by him to discharge his duties under this
Agreement, and Company shall defend Employee, at Company's expense, in connection with any and all claims by stockholders or third parties which are based upon actions taken by Employee to discharge
his duties under this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>9.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;PERSONAL CONDUCT.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Employee
agrees promptly and faithfully to comply with all present and future policies, requirements, directions, requests and rules and regulations of Company in connection with
Company's </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=6,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=475449,FOLIO='6',FILE='DISK032:[01WLA4.01WLA1204]HN1204B.;9',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hn1204_1_7"> </A>

<P><FONT SIZE=2>
business. Employee further agrees to conform to all laws and regulations and not at any time to commit any act or become involve in any situation or occurrence tending to bring Company into public
scandal, ridicule or which will reflect unfavorably on the reputation of Company. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>10.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;TERMINATION FOR CAUSE.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Company
reserves the right to declare Employee in default of this Agreement if Employee willfully breaches or habitually neglects the duties which he is required to perform under the
terms of this Agreement, or if Employee commits such acts of dishonesty, fraud, misrepresentation, gross negligence or willful misconduct as would prevent the effective performance of his duties or
which results in material harm to Company or its business. Company may terminate this Agreement for cause by giving written notice of termination to Employee. With the exception of the covenants
included in section&nbsp;3 above, upon such termination the obligations of Employee and Company under this Agreement shall immediately cease. Such termination shall be without prejudice to any other
remedy to which Company may be entitled either at law, in equity, or under this Agreement. If Employee's employment is terminated pursuant to this section, Company shall pay to Employee, immediately
upon such termination, any deferred or unpaid compensation to which Employee is entitled on the date of such termination. In the event of a termination pursuant to this section, Employee shall be
entitled to receive any accrued and unpaid amounts earned pursuant to sections&nbsp;5(a) and 5(b). All other rights Employee has under any benefit or stock option plans and programs shall be
determined in accordance with the terms and conditions of such plans and programs. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>11.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp;TERMINATION WITHOUT CAUSE.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(a)&nbsp;</B></FONT><FONT SIZE=2><B><I>Death.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee's employment shall terminate upon the death of Employee.
Upon such termination, the obligations of Employee and Company under this Agreement shall immediately cease. In the event of a termination pursuant to this section, Employee shall be entitled to
receive any accrued and unpaid amounts earned pursuant to sections&nbsp;5(a) and 5(b). All other rights Employee has under any benefit or stock option plans and programs shall be determined in
accordance with the terms and conditions of such plans and programs. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)&nbsp;</B></FONT><FONT SIZE=2><B><I>Disability.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Company reserves the right to terminate Employee's employment
upon ten (10) days written notice if, for a period of sixty (60) days, Employee is prevented from discharging his duties under this Agreement due to any physical or mental disability. With the
exception of the covenants included in section&nbsp;3 above, upon such termination the obligations of Employee and Company under this Agreement shall immediately cease. In the event of a termination
pursuant to this section, Employee shall be entitled to receive any accrued and unpaid amounts earned pursuant to sections&nbsp;5(a)
and 5(b). All other rights Employee has under any benefit or stock option plans and programs shall be determined in accordance with the terms and conditions of such plans and programs. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)&nbsp;</B></FONT><FONT SIZE=2><B><I>Election by Employee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee's employment may be terminated at any time by
Employee upon not less than sixty (60) days written notice by Employee to the Board. With the exception of the covenants included in section&nbsp;3 above, upon such termination the obligations of
Employee and Company under this Agreement shall immediately cease. In the event of a termination pursuant to this section, Employee shall be entitled to receive any accrued and unpaid amounts earned
pursuant to sections&nbsp;5(a) and 5(b). All other rights Employee has under any benefit or stock option plans and programs shall be determined in accordance with the terms and conditions of such
plans and programs. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=7,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=534867,FOLIO='7',FILE='DISK032:[01WLA4.01WLA1204]HN1204B.;9',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<BR>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_hp1204_1_8"> </A>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(d)&nbsp;</B></FONT><FONT SIZE=2><B><I>Election By Company.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Company may terminate Employee's employment upon not
less than thirty (30) days written notice by Company to Employee. With the exception of the covenants included in section&nbsp;3 above, upon such termination the obligations of Employee and Company
under this Agreement shall immediately cease. In the event of a termination pursuant to this section, Employee shall be entitled to receive (i) any accrued and unpaid amounts earned pursuant to
sections&nbsp;5(a) and 5(b), and (ii) compensation equal to the the base salary through the expiration date of the term, payable in accordance with the Company's payroll procedures as if Employee's
employment by Company had continued until the expiration of the term. All other rights Employee has under any benefit or stock option plans and programs shall be determined in accordance with the
terms and conditions of such plans and programs. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)&nbsp;</B></FONT><FONT SIZE=2><B><I>Severance Pay Upon Change of Control.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Upon the sale or disposition by
Company of substantially all of its business or assets or the sale of the capital stock of Company in connection with the sales or transfer of a controlling interest in Company to a third party or the
merger or consolidation of Company with another corporation as part of a sale or transfer of a controlling interest in Company to a third party and employee is terminated because of the change of
control or employee decides within 30 days after change of control that he cannot work with the new management; then Employee shall receive as additional compensation and not in lieu of his rights
under this Agreement, one (1) years' salary. "A controlling interest" shall be defined as 50% or more of the common stock of the Company. "One (1) years' salary" shall be defined as only the cash
compensation paid to Employee pursuant to subparagraph (a) above, as it may be modified from time to time, and shall not include employee benefits, incentive stock options, automobile allowance or
debt forgiveness, if any. Employee shall be entitled to receive this additional compensation if Employee's employment is terminated as a result of such change of control in addition to payment due
under the remainder of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>12.&nbsp;&nbsp;MISCELLANEOUS.</B></FONT><FONT SIZE=2><B>&nbsp;&nbsp; </B></FONT></P>

<P><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;</B></FONT><FONT SIZE=2><B><I>Preparation of Agreement.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;It is acknowledged by each party that such party either had separate and
independent advice of counsel or the opportunity to avail itself or himself of same. In light of these facts it is acknowledged that no party shall be construed to be solely responsible for the
drafting hereof, and therefore any ambiguity shall not be construed against any party as the alleged draftsman of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(b)&nbsp;</B></FONT><FONT SIZE=2><B><I>Cooperation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each party agrees, without further consideration, to cooperate
and diligently perform any further acts, deeds and things and to execute and deliver any documents that may from time to time be reasonably necessary or otherwise reasonably required to consummate,
evidence, confirm and/or carry out the intent and provisions of this Agreement, all without undue delay or expense. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(c)&nbsp;</B></FONT><FONT SIZE=2><B><I>Interpretation.</I></B></FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;</FONT><FONT
SIZE=2><B><I>Entire Agreement/No Collateral Representations.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each party expressly acknowledges and agrees that
this Agreement, including all exhibits attached hereto: (1) is the final, complete and exclusive statement of the agreement of the parties with respect to the subject matter hereof; (2) supersedes any
prior or contemporaneous agreements, promises, assurances, guarantees, representations, understandings, conduct, proposals, conditions, commitments, acts, course of dealing, warranties,
interpretations or terms of any kind, oral or written (collectively and severally, the "Prior Agreements"), and that any such prior agreements are of no force or effect except as expressly set forth
herein; and (3) may not be varied, supplemented or contradicted by evidence of Prior Agreements, or by evidence of subsequent oral agreements. Any agreement hereafter made shall be ineffective to
modify, supplement or discharge the terms of this Agreement, in whole or in part, unless such agreement is in writing and signed by the party against whom enforcement of the modification or supplement
is sought. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=8,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=289203,FOLIO='8',FILE='DISK032:[01WLA4.01WLA1204]HP1204A.;14',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hp1204_1_9"> </A>
<UL>
<UL>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;</FONT><FONT SIZE=2><B><I>Waiver.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;No breach of any agreement or provision herein contained, or of any obligation under this
Agreement, may be waived, nor shall any extension of time for performance of any obligations or acts be deemed an extension of time for performance of any other obligations or acts contained herein,
except by written instrument signed by the party to be charged or as otherwise expressly authorized herein. No waiver of any breach of any agreement or provision herein contained shall be deemed a
waiver of any preceding or succeeding breach thereof, or a waiver or relinquishment of any other agreement or provision or right or power herein contained. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;</FONT><FONT
SIZE=2><B><I>Remedies Cumulative.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;The remedies of each party under this Agreement are cumulative and shall not
exclude any other remedies to which such party may be lawfully entitled. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;</FONT><FONT
SIZE=2><B><I>Severability.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;If any term or provision of this Agreement or the application thereof to any person
or circumstance shall, to any extent, be determined to be invalid, illegal or unenforceable under present or future laws effective during the term of this Agreement, then and, in that event: (A) the
performance of the offending term or provision (but only to the extent its application is invalid, illegal or unenforceable) shall be excused as if it had never been incorporated into this Agreement,
and, in lieu of such excused provision, there shall be added a provision as similar in terms and amount to such excused provision as may be possible and be legal, valid and enforceable, and (B) the
remaining part of this Agreement (including the application of the offending term or provision to persons or circumstances other than those as to which it is held invalid, illegal or unenforceable)
shall not be affected thereby and shall continue in full force and effect to the fullest extent provided by law. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;</FONT><FONT
SIZE=2><B><I>Time is of the Essence.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;It is expressly understood and agreed that time of performance is strictly
of the essence with respect to each and every term, condition, obligation and provision hereof and that the failure to timely perform any of the terms, conditions, obligations or provisions hereof by
any party
shall constitute a material breach and a noncurable (but waivable) default under this Agreement by the party so failing to perform. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;</FONT><FONT
SIZE=2><B><I>No Third Party Beneficiary.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Notwithstanding anything else herein to the contrary, the parties
specifically disavow any desire or intention to create any third party beneficiary obligations, and specifically declare that no person or entity, other than as set forth in this Agreement, shall have
any rights hereunder or any right of enforcement hereof. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;(vii)&nbsp;</FONT><FONT
SIZE=2><B><I>No Reliance Upon Prior Representation.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;The parties acknowledge that no other party has made any
oral representation or promise which would induce them prior to executing this Agreement to change their position to their detriment, partially perform, or part with value in reliance upon such
representation or promise; the parties acknowledge that they have taken such action at their own risk; and the parties represent that they have not so changed their position, performed or parted with
value prior to the time of their execution of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;(viii)&nbsp;</FONT><FONT
SIZE=2><B><I>Headings; References; Incorporation; Gender.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;The headings used in this Agreement are for
convenience and reference purposes only, and shall not be used in construing or interpreting the scope or intent of this Agreement or any provision hereof. References to this Agreement shall include
all amendments or renewals thereof. Any exhibit referenced in this Agreement shall be construed to be incorporated in this Agreement. As used in this Agreement, each gender shall be deemed to include
the other gender, including neutral genders or genders appropriate for entities, if applicable, and the singular shall be deemed to include the plural, and vice versa, as the context requires. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=9,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=346894,FOLIO='9',FILE='DISK032:[01WLA4.01WLA1204]HP1204B.;8',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hp1204_1_10"> </A>
<UL>
<UL>
<BR>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(d)&nbsp;</B></FONT><FONT SIZE=2><B><I>Enforcement.</I></B></FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;</FONT><FONT
SIZE=2><B><I>Applicable Law.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement and the rights and remedies of each party arising out of or relating
to this Agreement (including, without limitation, equitable remedies) shall be solely governed by, interpreted under, and construed and enforced in accordance with the laws (without regard to the
conflicts of law principles thereof) of the State of California, as if this agreement were made, and as if its obligations are to be performed, wholly within the State of California. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;</FONT><FONT
SIZE=2><B><I>Consent to Jurisdiction; Service of Process.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Any action or proceeding arising out of or relating to
this Agreement shall be filed in and heard and litigated solely before the state courts of California located within the County of Los Angeles. Each party generally and unconditionally accepts the
exclusive jurisdiction of such courts and to venue therein, consents to the service of process in any such action or proceeding by certified or registered mailing of the summons and complaint in
accordance with the notice provisions of this Agreement, and waives any defense or right to object to venue in said courts based upon the doctrine of "Forum Non Conveniens". Each party irrevocably
agrees to be bound by any judgement rendered thereby in connection with this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;</FONT><FONT
SIZE=2><B><I>Waiver of Right to Jury Trial.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each party hereby waives such party's respective right to a jury
trial of any claim or cause of action based upon or arising out of this Agreement. Each party acknowledges that this waiver is a material inducement to each other party hereto to enter into the
transaction contemplated hereby, that each other party has already relied upon this waiver in entering into this Agreement, and that each other party will continue to rely on this waiver in their
future dealings. Each party warrants and represents that such party has reviewed this waiver with such party's legal counsel, and that such party has knowingly and voluntarily waived its jury trial
rights following consultation with legal counsel. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;</FONT><FONT
SIZE=2><B><I>Consent to Specific Performance and Injunctive Relief and Waiver of Bond or Security.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Each party
acknowledges that Company may, as a result of Employee's breach of the covenants and obligations included in section 3 of this Agreement, sustain immediate and long-term substantial and irreparable
injury and damage which cannot be reasonably or adequately compensated by damages at law. Each party agrees that in the event of Employee's breach or threatened breach of the covenants and obligations
included in section 3, Company shall be entitled to obtain from a court of competent jurisdiction or arbitration, as the case may be under this Agreement, equitable relief, including, without
limitation, enforcement of all of the provisions of this Agreement by specific performance and/or temporary, preliminary and/or permanent injunctions enforcing any of Company's rights, requiring
performance by Employee, or enjoining any breach by Employee, all without proof of any actual damages that have been or may be caused to Company by such breach or threatened breach and without the
posting of bond or other security in connection therewith. Employee waives the claim or defense that Company has an adequate remedy at law and Employee shall not allege or otherwise assert the legal
position that any such remedy at law exists. Each party agrees and acknowledges: (1) that the terms of this section are fair, reasonable and necessary to protect the legitimate interests of the other
party; (2) that this waiver is a material inducement to the other party to enter into the transaction contemplated hereby; (3) that the other party has already relied upon this waiver in entering into
this Agreement; and (4) that each party will continue to rely on this waiver in their future dealings. Each party warrants and represents that such party has reviewed this provision with such party's
legal counsel, and that such party has knowingly and voluntarily waived its rights following consultation with legal counsel. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=10,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=920489,FOLIO='10',FILE='DISK032:[01WLA4.01WLA1204]HP1204B.;8',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<UL>
<UL>
<BR>
</UL>
</UL>
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->

<P><FONT SIZE=2><A
NAME="page_hr1204_1_11"> </A> </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;</FONT><FONT
SIZE=2><B><I>Attorneys' Fees and Costs.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;If any party institutes or should the parties otherwise become a party to
any Action Or Proceeding (as defined below) based upon or arising out of this Agreement including, without limitation, to enforce or interpret this Agreement or any provision hereof, or for damages by
reason of any alleged breach of this Agreement or any provision hereof, or for a declaration of rights in connection herewith, or for any other relief, including equitable relief, in connection
herewith, the Prevailing Party in any such Action Or Proceeding, whether or not such Action Or Proceeding proceeds to final judgement or determination, shall be entitled to receive from the
non-Prevailing Party as a cost of suit, and not as damages, all Costs And Expenses (as defined below) of prosecuting or defending the Action Or Proceeding, as the case may be, including, without
limitation, reasonable Attorneys' And Other Fees. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;</FONT><FONT
SIZE=2><I>Definitions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The term "Action Or Proceeding" is defined as any and all claims, suits, actions,
notices, inquiries, proceedings, hearings, arbitrations or other similar proceedings, including appeals and petitions therefrom, whether formal or informal, governmental or non-governmental, or civil
or criminal. The term "Prevailing Party" is defined as the party who is determined to prevail by the Court after its consideration of all damages and equities in the Action Or Proceeding, whether or
not the Action Or Proceeding proceeds to final judgment. The Court shall retain the discretion to determine that no party is the Prevailing Party in which case no party shall be entitled to recover
its Costs And Expenses under this subsection 12(d). The term "Attorneys' And Other Fees" is defined as attorneys' fees, accountants' fees, fees of other professionals, witness fees (including experts
engaged by the parties, but excluding shareholders, officers, employees or partners of the parties), and any and all other similar fees incurred in the prosecution or defense of the Action Or
Proceeding. The term "Costs And Expenses" is defined as the cost to take depositions, the cost to arbitrate this dispute, if applicable, and the costs and expenses of travel and lodging incurred with
respect to the Action Or Proceeding, provided, however, the party incurring said travel and lodging expense must ordinarily travel over one hundred (100) miles, one way, from his or her residence in
incurring such expense. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(e)&nbsp;</B></FONT><FONT SIZE=2><B><I>No Assignment of Rights or Delegation of Duties by Employee.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Employee's
rights and benefits under this Agreement are personal to him and therefore (i) no such right or benefit shall be subject to voluntary or involuntary alienation, assignment or transfer, and (ii)
Employee may not delegate his duties or obligations hereunder. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(f)&nbsp;&nbsp;</B></FONT><FONT SIZE=2><B><I>Notices.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;Unless otherwise specifically provided in this Agreement, all
notices, demands, requests, consents, approvals or other communications (collectively and severally called "Notices") required or permitted to be given hereunder, or which are given with respect to
this Agreement, shall be in writing, and shall be given by: (A) personal delivery (which form of Notice shall be deemed to have been given upon delivery), (B) by telegraph or by private
airborne/overnight delivery service (which forms of Notice shall be deemed to have been given upon confirmed delivery by the delivery agency), (C) by electronic or facsimile or telephonic
transmission, provided the receiving party has a compatible device or confirms receipt thereof (which forms of Notice shall be deemed delivered upon confirmed transmission or confirmation of receipt),
or (D) by mailing in the United States mail by registered or
certified mail, return receipt requested, postage prepaid (which forms of Notice shall be deemed to have been given upon the fifth (5th) business day following the date mailed). Each party, and their
respective counsel, hereby agree that if Notice is to be given hereunder by such party's counsel, such counsel may communicate directly with all principals, as required to comply with the foregoing
notice provisions. Notices shall be addressed to the address hereinabove set forth in the introductory paragraph of this Agreement, or to such other address as the receiving party shall have specified
most recently by like Notice, with a copy to the other parties hereto. Any Notice given to the estate of a party shall be sufficient if addressed to the party as provided in this subsection. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=11,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=113062,FOLIO='11',FILE='DISK032:[01WLA4.01WLA1204]HR1204A.;11',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<A NAME="page_hr1204_1_12"> </A>
<BR>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>(g)&nbsp;</B></FONT><FONT SIZE=2><B><I>Counterparts.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement may be executed in counterparts, each of which
shall be deemed an original, and all of which together shall constitute one and the same instrument, binding on all parties hereto. Any signature page of this Agreement may be detached from any
counterpart of this Agreement and reattached to any other counterpart of this Agreement identical in form hereto by having attached to it one or more additional signature pages. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>(h)&nbsp;</B></FONT><FONT SIZE=2><B><I>Execution by All Parties Required to be Binding: Electronically Transmitted
Documents.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;This Agreement shall not be construed to be an offer and shall have no force and effect until this Agreement is fully executed by all parties hereto.
If a copy or counterpart of this Agreement is originally executed and such copy or counterpart is thereafter transmitted electronically by facsimile or similar device, such facsimile document shall
for all purposes be treated as if manually signed by the party whose facsimile signature appears. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the parties have executed this Agreement. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><B>Company:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
STAAR SURGICAL COMPANY,<BR>
a Delaware corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>JOHN R. WOLF</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2><B>Employee:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>JOHN SANTOS</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> John Santos</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=12,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3",CHK=566601,FOLIO='12',FILE='DISK032:[01WLA4.01WLA1204]HR1204A.;11',USER='TOSBORNA',CD=';4-MAY-2001;17:11' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01WLA1211_3">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_hl1204_1">Exhibit 10.32</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hl1204_2">EMPLOYMENT AGREEMENT</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hl1204_3">RECITALS</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hl1204_4">AGREEMENT</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=DMALONE,SEQ=,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="3" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.58
<SEQUENCE>4
<FILENAME>a2041391zex-10_58.htm
<DESCRIPTION>EX-10-58
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01WLA1211_4">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P><FONT SIZE=2><A
NAME="page_ht1204_1_1"> </A> </FONT></P>

<!-- TOC_END -->

<P><FONT SIZE=2><B>[CIBC WORLD MARKETS LETTERHEAD]  </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="ht1204_exhibit_10.58"> </A>
<A NAME="toc_ht1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit 10.58    <BR>  </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;
September 8, 2000 </FONT></P>

<P><FONT SIZE=2><B>PERSONAL AND CONFIDENTIAL  </B></FONT></P>

<P><FONT SIZE=2>Andrew
F. Pollet<BR>
Chairman<BR>
STAAR Surgical Company<BR>
1911 Walker Avenue<BR>
Monrovia, California 91016 </FONT></P>

<P><FONT SIZE=2>Dear
Mr. Pollet: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This
letter will confirm the understanding and agreement (the "Agreement") among CIBC World Markets Corp. (the "Lead Placement Agent"), Adams, Harkness&nbsp;&amp; HIll, Inc. (the
"Co-Placement Agent") (collectively, the "Agents") and STAAR Surgical Company (the "Company") as follows: </FONT></P>

<DL compact>
<DT><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2><B>Engagement:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT><FONT SIZE=2>The Company hereby engages the Agents as its exclusive agents in
the private placement of one or more classes or series of securities of the Company to a limited number of sophisticated investors (the "Investors"), pursuant to the following terms and conditions.
Such securities (the "Securities") may take the form of common stock or other equity-linked securities. Such placement shall be referred to as the "Transaction." </FONT></DD></DL>
<BR>
<UL>

<P><FONT SIZE=2>Currently,
the Company plans to sell up to 1,500,000 shares of it's common stock. The selection of each of the Investors from a list of potential Investors and the number of shares sold to each of
such Investors shall be mutually agreed by the Company and the Agents. The number and price of the Securities the Company shall ultimately agree to sell, pursuant to the Purchase Agreements (defined
below), are entirely within its discretion. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2><B>The Agents' Role:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Agents hereby accept the engagement described herein and, in that connection, agree to:
<BR><BR></FONT>
<DL compact>
<DT><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>assist
in preparing a private placement memorandum (the "Memorandum") describing the Company and the Securities;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>review
with the Company a list of the Investors to whom the Memorandum will be provided;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>prepare
other communications to be used in placing the Securities, whether in the form of letter, circular, notice or otherwise, and
<BR><BR></FONT></DD><DT><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>assist
and advise the Company with respect to the negotiation of the sale of the Securities to the Investors. </FONT></DD></DL>
</DD></DL>
<UL>
<BR>
</UL>
<DL compact>
<DT><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2><B>Due Diligence:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;It is understood that the Agents' assistance in the Transaction will be subject to the satisfactory
completion of such investigation and inquiry into the affairs of the Company as the Agents deem appropriate under the circumstances (such investigation hereinafter to be referred to as "Due
Diligence") and the approval of each Agents' internal committees. Each Agent shall have the right, in its sole discretion, to terminate its involvement in the Transaction if the outcome of the Due
Diligence is not to its satisfaction or if approval of its internal committees is not obtained. The termination by any one of the Agents shall not be imputed to the other Agents. If both Agents
exercise their discretion to terminate their involvement in the Transaction, then this Agreement will terminate ("Early Termination"). </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=773807,FOLIO='1',FILE='DISK032:[01WLA4.01WLA1204]HT1204A.;16',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_2"> </A>
<DL compact>
<DT><FONT SIZE=2>4.</FONT></DT><DD><FONT SIZE=2><B>Term; Exclusivity:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The term of the Agreement shall extend from the date hereof until the earlier of September 8, 2001
or Early Termination, and that during the term of this Agreement: (1)&nbsp;the Company will not, and will not permit its representatives to, other than in coordination with the Lead Placement Agent,
contact or solicit institutions, corporations or other entities as potential purchasers of the Securities and (ii)&nbsp;the Company will not pursue any financing transaction which would be in lieu
of a Transaction. Futhermore, the Company agrees that during the term of the Agreement all inquiries, whether direct or indirect, from prospective Investors will be referred to the Lead Placement
Agent and will be deemed to have been contacted by the Lead Placement Agent in connection with the Transaction. The Company may reject any potential Investor if in its discretion, the Company believes
that the inclusion of such Investor in the Company would be incompatible with the best interests of the Company. The Company shall not be obligated to sell the Securities or to accept any offer
thereof, and the terms of such Securities and the final decision to issue the same shall be subject to the discretionary approval of the Company. </FONT></DD></DL>
<UL>

<P><FONT SIZE=2>Any
party may terminate its engagement at any time by giving the other parties at least thirty (30) days prior written notice of such termination, at which time the Company shall reimburse the Agents
for all reasonable expenses incurred, in accordance with Paragraph&nbsp;9 hereof. The Company agrees to pay the Agents any fees specified in Paragraph&nbsp;8 if the events specified therein shall
occur during the term of this Agreement or within twelve months after the termination or expiration of this Agreement. Any obligation pursuant to this Paragraph 4 shall survive the termination or
expiration of this Agreement. </FONT></P>

<P><FONT SIZE=2>No
offers or sales of any securities of the same or similar class as the Securities will be made by the Company or any affiliate during the six-month period after the completion of the offering of the
Securities in each case except in compliance with the registration requirements of the Securities Act of 1933, as amended, or an exemption therefrom (the "Securities Act"). </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>5.</FONT></DT><DD><FONT SIZE=2><B>Best Efforts:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;It is understood that the Agents' involvement in the Transaction is strictly on a best efforts basis
and that the consummation of the Transaction will be subject to, among other things, market conditions.
<BR><BR></FONT></DD><DT><FONT SIZE=2>6.</FONT></DT><DD><FONT SIZE=2><B>Information:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT><FONT SIZE=2>The Company shall furnish, or cause to be furnished, to the Agents
and to the Investors all information reasonably requested by the Agents for the purpose of rendering services hereunder or in connection with the purchase of the Securities, including the Memorandum
(and together with all such other information, the "Information"). In addition, the Company agrees to make available to the Agents upon request from time to time the officers, directors, accountants,
counsel and other advisors of the Company. The Company recognizes and </FONT><P><FONT SIZE=2>confirms
that the Agents (a)&nbsp;will use and rely on the information (including the Memorandum that will be delivered to each of the Investors) and on information available from generally
recognized public sources in performing the services contemplated by this Agreement without having independently verified the same; (b)&nbsp;does not assume responsibility for the accuracy or
completeness of the Memorandum or the Information and such other information; and (c)&nbsp;will not make an appraisal of any of the assets or liabilities of the Company. </FONT></P>

</DD></DL>
<UL>

<P><FONT SIZE=2>The
Company represents and warrants to the Agents that: (i)&nbsp;all such information, including the Memorandum, any documents attached as exhibits thereto and/or incorporated by reference therein,
and any communications prepared pursuant to paragraph 2(a) above, will be true and accurate in all material respects and does not and will not contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements made in the light of the circumstances under which they were made, not misleading and (ii)&nbsp;any projected financial information
or other forward-looking information which the Campany provided to the </FONT></P>

</UL>
<P ALIGN="CENTER"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=1003535,FOLIO='2',FILE='DISK032:[01WLA4.01WLA1204]HT1204A.;16',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_3"> </A>
<UL>

<P><FONT SIZE=2>
Agent will be made by the Company in good faith, based on management's best estimates then available and based on facts and assumptions which the Company believes to be reasonable. The Company agrees
that, upon reasonable request, it will meet with the Agents or its representatives to discuss all information relevant for disclosure in the Memorandum and will cooperate in any investigation
undertaken by the Agents thereof, including any document included or incorporated by reference therein. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>7.</FONT></DT><DD><FONT SIZE=2><B>Company's Responsibilities, Representations and Warranties:</B></FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>The
sale of Securities to any Investor will be evidenced by a purchase agreement ("Purchase Agreement") between the Company and such Investor in a form reasonably satisfactory to
the Company and the Agents. Prior to the signing of any Purchase Agreement, officers of the Company with responsibility for financial affairs will be available to answer inquires from prospective
investors.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>The
selling price of the Securities to be issued and sold by the Company pursuant to the Purchase Agreements will be specified in writing by the Agents on behalf of the Company to
the prospective investors prior to the execution of the Purchase Agreements, subject to the Company's approval.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>The
Company will perform the covenants set forth in the Purchase Agreements. The Purchase Agreements will require the Company to file, as soon as practicable after it has signed and
delivered such Purchase Agreements (the "Closing") but in any event no later than two weeks following the Closing, a registration statement with the Securities and Exchange Commission (the "SEC") for
the resale from time to time of the Securities to be issued pursuant to such Purchase Agreements (the "Registration Statement"). The Company will not modify any such Purchase Agreements, nor will it
execute and deliver any additional Purchase Agreements after the time it has filed the Registration Statement.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>The
Company (i) represents and warrants that the representations and warranties contained in the Purchase Agreements will be true and correct in all respects on the date of such
Purchase Agreements and on the Closing Date and (ii) agrees that the Agents shall be entitled to rely on such representations and warranties as if they were made directly to the Agents.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(e)</FONT></DT><DD><FONT SIZE=2>The
Company agrees that the Company shall have sole responsibility for ensuring that the sale of Securities contemplated by this Agreement shall be exempt from registration
requirements of the Securities Act, and will otherwise comply with the securities laws of any applicable country or other jurisdiction. The Company shall not take any action or permit to be taken any
action on its behalf that would cause such sale of securities to fail (i)&nbsp;qualify for such an exemption, or (ii)&nbsp;otherwise comply with such securities laws. The Company hereby
represents, warrants and covenants that the Company has not, and agrees that it will not, directly or indirectly, engage in any form of general solicitation or general advertising or directed selling
efforts.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(f)</FONT></DT><DD><FONT SIZE=2>At
the Closing, the Company will cause its independent public accountants to address and deliver to the Company and the Agents a letter or letters (which letters are frequently
referred to as "Comfort Letters") dated as of the Closing, which letter or letters shall be in the form reasonably satisfactory to the agents.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(g)</FONT></DT><DD><FONT SIZE=2>At
the Closing, the Company will cause its counsel to address and deliver to the Company and the Agents (stating that each of the Investors may rely thereon as if directly addressed
to each of them) an opinion satisfactory to the Agents, dated as of the Closing, with respect to such </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=362221,FOLIO='3',FILE='DISK032:[01WLA4.01WLA1204]HT1204A.;16',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_4"> </A>
<UL>
<UL>

<P><FONT SIZE=2>matters
as the Agents and its counsel shall reasonably request, including opinions customary for transactions of the type contemplated by this Agreement, including an opinion that the offering and </FONT></P>


<P><FONT SIZE=2>sale
of the Securities are not required to be registered under the Securities Act, as well as an opinion substantially in the form of Annex A hereto. In rendering such opinion, such counsel may rely
upon the representations and warranties of the purchasers contained in the Purchase Agreements and upon certificates from officers of the company as to factual matters. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>(h)</FONT></DT><DD><FONT SIZE=2>The
Company will cause its outside intellectual property and/or regulatory counsel to deliver one or more opinions satisfactory to the Agents, dated as of the Closing, to the Agents
regarding such matters as the Agents and its counsel shall reasonably request. Furthermore, the Company acknowledges that the Purchase Agreements will require the Company's counsel, its intellectual
property counsel and/or its regulatory counsel to deliver one or more opinions to the Investors. The Company agrees that the Agents shall be entitled to rely on any opinions delivered as the Investors
in connection with the Transaction and resale of the Securities under the Registration Statement.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>The
Company agrees that it will not consummate the sale of the Securities unless it delivers or causes to be delivered the items described in paragraphs (f) through (h) above to
the Agents at the Closing.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(j)</FONT></DT><DD><FONT SIZE=2>For
a period of ninety (90) days from the effective date of the Registration Statement, the Company will not, without the prior written consent of the Lead Placement Agent, sell,
contract to sell or otherwise dispose of or issue any securities of the Company, except pursuant to previously issued options, any agreements providing for anti-dilution or other stock purchase or
share issuance rights in existence on the date hereof, any employee benefit or similar plan of the Company in existence on the date hereof, or any technology license agreement, strategic alliance or
joint venture in existence on the date hereof or which the Company may enter into hereafter. This paragraph shall not apply to the sale of the Company to any third party.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(k)</FONT></DT><DD><FONT SIZE=2>During
the time the Registration Statement is effective covering the resales of any Securities sold to Investors, the Company will furnish to the Agents:
<BR><BR></FONT>
<DL compact>
<DT><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>as
soon as practicable (but in the case of the annual report of the Company to its stockholders, within 120 days after the end of each fiscal year
of the Company), one copy of: (a) its annual report to its stockholders (which annual report shall contain financial statements audited in accordance with generally accepted accounting principles in
the United States by a firm of certified public accountants of recognized standing), (b) if not included in substance in its annual report to stockholders, its annual report on Form 10-K, (c) each of
its quarterly reports to its stockholders and, if not included in substance in its quarterly report to stockholders, its quarterly report on Form 10-Q and any other </FONT><P><FONT SIZE=2>document
or agreement that is incorporated by reference into the Registration Statement, and (d) the full Registration Statement (the foregoing in each case, excluding exhibits); and </FONT></P>

</DD><DT><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>upon
reasonable request, all exhibits excluded by the parenthetical to the last clause of the immediately preceding paragraph and all other
information that is generally available to the public. </FONT></DD></DL>
</DD></DL>
<BR>
</UL>
<DL compact>
<DT><FONT SIZE=2>8.</FONT></DT><DD><FONT SIZE=2><B>Fees.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;As compensation for the services to be rendered by the Agents hereunder, the
Company will pay the Agents at the Closing, by wire transfer of immediately available funds, from the </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=368172,FOLIO='4',FILE='DISK032:[01WLA4.01WLA1204]HT1204A.;16',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_5"> </A>
<UL>

<P><FONT SIZE=2>proceeds
of the sale of the Securities, a transaction fee (the "Transaction Fee") equal to 7.0% of the gross proceeds raised from the sale of the Securities. 70.0% of the Transaction Fee shall be paid
to CIBC World Markets Corp. and 30.0% of the Transaction Fee shall be paid to Adams, Harkness &amp; Hill, Inc. Further, the Company will pay the Agents the Transaction Fee if within twelve months from the
termination of this Agreement the Company reaches an agreement in principle for the sale of the Securities to any Investors which the Agents previously solicited or sought to solicit (but were not
permitted to do so due to the Company's rejection of such proposed Investors pursuant to the third sentence of Section 4 hereof) on its behalf or from which the Company has received any inquiry
pursuant to Section 4 hereof. The preceding sentence will not apply to any securities sold to Pharmacia Corporation. Upon the Company's request, at the termination or expiration of this Agreement, the
Agents will supply the Company with a list of Investors which the Agents have solicited or sought to solicit (but were not permitted to do so due to the Company's rejection of such proposed Investors
pursuant to the third sentence of Section 4 hereof) on its behalf. The Company's obligations hereunder shall survive the termination or expiration of this Agreement. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>9.</FONT></DT><DD><FONT SIZE=2><B>Expense Reimbursement:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In addition to the Transaction Fee, and regardless of whether
the sale of the Securities contemplated hereby is consummated, the Company agrees to reimburse the Agents for all of its reasonable out-of-pocket expenses in connection with the performance of its
activities under the terms of this Agreement. Reasonable out-of-pocket expenses include, but are not limited to, costs such as printing, telephone, telex, courier service, direct computer expenses,
accommodations and travel. The Company will reimburse the Agents for fees and expenses of legal counsel employed by and for the Agents, if any, in connection with this Agreement and the engagement
hereunder. All such fees, expenses and costs shall be reimbursed promptly upon submission by the Lead Placement Agent of the expenses to be reimbursed to each of the Agents. The parties' obligations
under this paragraph shall survive the termination or expiration of this Agreement. The Agents estimate that the expenses will be approximately $50,000.
<BR><BR></FONT></DD><DT><FONT SIZE=2>10.</FONT></DT><DD><FONT SIZE=2><B>Indemnity.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In addition to the fees and reimbursement of expenses provided for above,
the parties agree to the indemnification provisions set forth as Annex B hereto, which are incorporated herein by reference as if fully set forth below. The parties' obligations under this paragraph
shall survive the termination or expiration of this Agreement.
<BR><BR></FONT></DD><DT><FONT SIZE=2>11.</FONT></DT><DD><FONT SIZE=2><B><I>GOVERNING LAWS</I></B></FONT><FONT SIZE=2><B>:&nbsp;&nbsp;THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND INTERPRETED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE CONFLICT OF LAWS PROVISIONS THEREOF.  </B></FONT></DD></DL>
<UL>

<P><FONT SIZE=2><B>THE COMPANY IRREVOCABLY SUBMITS TO THE JURISDICTION OF ANY COURT OF THE STATE OF NEW YORK, IN NEW YORK, NEW YORK, FOR THE PURPOSE OF ANY SUIT, ACTION OR OTHER PROCEEDING
ARISING OUT OF THIS LETTER AGREEMENT OR OUR ENGAGEMENT HEREUNDER. EACH OF THE COMPANY AND CIBC WORLD MARKETS HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BROUGHT BY
OR ON BEHALF OF EITHER PARTY BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS LETTER AGREEMENT, OUR ENGAGEMENT HEREUNDER OR THE TRANSACTIONS CONTEMPLATED HEREBY.  </B></FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2><B>12.</B></FONT></DT><DD><FONT SIZE=2><B> Confidentiality.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Except as required by law, this Agreement and the services and advice to be provided by the
Agents hereunder, shall not be disclosed to third parties without the Agents' prior written permission. Notwithstanding, the Agents shall be permitted to advertise the services it provided in
connection with the private placement subsequent to the consummation of the private placement. Such expense shall not be reimbursable under paragraph 9 hereof. </FONT></DD></DL>
<P ALIGN="CENTER"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=5,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=420226,FOLIO='5',FILE='DISK032:[01WLA4.01WLA1204]HT1204A.;16',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_7"> </A>
<DL compact>
<DT><FONT SIZE=2>13.</FONT></DT><DD><FONT SIZE=2><B>No Brokers:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;</FONT><FONT SIZE=2>The company represents and warrants
to the Agents that there are no brokers, representatives or other persons which have an interest in compensation due to the Agents from any transaction contemplated herein or which would otherwise be
due any fee, commission or remuneration upon consummation of any Transaction. The Company hereby represents and warrants to the Agents that during the term of this engagement, the Company will not
have, prior to the Closing, any discussions with any person other than representatives of the Agents for the purpose of engaging, or considering the engagement of, such person as a finder or broker in
connection with the sale by the Company of the Securities covered by this letter to prospects in the United States of America or overseas.
<BR><BR></FONT></DD><DT><FONT SIZE=2>14.</FONT></DT><DD><FONT SIZE=2><B>Authorization:</B></FONT><FONT SIZE=2>&nbsp;The Company and the Agents represent and warrant that each has all
requisite power and authority to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any
agreement, document or instrument to which it is a party or bound.
<BR><BR></FONT></DD><DT><FONT SIZE=2>15.</FONT></DT><DD><FONT SIZE=2><B>Miscellaneous:</B></FONT><FONT SIZE=2>&nbsp;This Agreement constitutes the entire understanding and agreement between
the Company and the Agents with respect to the subject matter hereof and supersedes all prior understanding or agreements between the parties with respect thereto, whether oral or written, express or
implied. Any amendments or modifications must be executed in writing by both parties. This Agreement and all rights, liabilities and obligations hereunder shall be binding upon and inure to the
benefit of each party's successors but may not be assigned without the prior written approval of the other party. This Agreement may be executed in any number of counterparts, each of which shall be
deemed to be an original, but such counterparts shall, together, constitute only one instrument. The descriptive headings of the Paragraphs of this Agreement are inserted for convenience only, do not
constitute a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. </FONT></DD></DL>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Agents are delighted to accept this engagement and look forward to working with you. Please confirm that the foregoing correctly sets forth our agreement by signing the enclosed
duplicate of this </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=6,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=600428,FOLIO='7',FILE='DISK032:[01WLA4.01WLA1204]HT1204B.;1',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_8"> </A>
<BR>

<P><FONT SIZE=2>
letter in the space provided and returning it, whereupon this letter shall constitute a binding agreement as of the date first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2>Very truly yours,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2>CIBC WORLD MARKETS CORP.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>MICHAEL FEKETE</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Michael Fekete<BR></FONT> <FONT SIZE=2><I>Managing Director</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><BR><FONT SIZE=2>ADAMS, HARKNESS &amp; HILL, INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="47%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="45%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>GREGORY BROWN, M.D.</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Gregory Brown, M.D.<BR></FONT> <FONT SIZE=2><I>Managing Director</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="78%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2>ACCEPTED AND AGREED TO<BR>
AS OF THE ABOVE DATE:</FONT></TD>
<TD WIDTH="3%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
STAAR Surgical Company</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="44%" ALIGN="CENTER"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>ANDREW F. POLLET</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Andrew F. Pollet<BR></FONT> <FONT SIZE=2><I>Chairman</I></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="48%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=7,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=977684,FOLIO='8',FILE='DISK032:[01WLA4.01WLA1204]HT1204B.;1',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_9"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ht1204_annex_a"> </A>
<A NAME="toc_ht1204_2"> </A>
<BR></FONT><FONT SIZE=2><B>ANNEX A    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The opinion of counsel to the Company shall be to the effect that nothing has come to their attention that caused them to believe that either the Registration
Statement of the Company (the "Registration Statement") or the Private Placement Memorandum (the "Private Placement Memorandum"), each as of its date (or if any amendment thereof or supplement thereto
has been made on or prior to the date of such opinion, then as of the date of such amendment or supplement) and as of the Closing, contained or contains an untrue statement of a material fact or
omitted or omits to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading (it being understood no opinion is expressed with respect to
the financial statements and related notes, financial statement schedules and other financial information included or incorporated by reference therein or omitted therefrom.) </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=8,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=620314,FOLIO='9',FILE='DISK032:[01WLA4.01WLA1204]HT1204B.;1',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_10"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="ht1204_annex_b__indemnification"> </A>
<A NAME="toc_ht1204_3"> </A>
<BR></FONT><FONT SIZE=2><B>ANNEX B: INDEMNIFICATION    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to indemnify and hold harmless the Agents and their affiliates and their respective directors, officers, employees, agents and controlling
persons (each such person, including the Agents, an "Indemnified Party") from and against any losses, claims, damages and liabilities, joint or several (collectively, the "Damages"), to which such
Indemnified Party may become subject in connection with or otherwise relating to or arising from (i)&nbsp;any transaction contemplated by this Agreement or the engagement of or performance of
services by an Indemnified Party thereunder or (ii)&nbsp;an untrue statement or an alleged untrue statement of a material fact or the omission or alleged omission to state a material fact necessary
in order to make a statement not misleading in light of the circumstances under which its was made, and will reimburse each Indemnified Party for all fees and expenses (including the fees and expenses
of counsel) (collectively, "Expenses") as incurred in connection with investigating, preparing, pursuing or defending any threatened or pending claim, action, proceeding or investigation
(collectively, the "Proceedings") arising therefrom, whether or not such Indemnified Party is a formal party to such Proceeding; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, that the
Company will not be liable to any such Indemnified Party to the extent that any Damages are found in a final non-appealable judgment by a court of competent jurisdiction to have resulted from the
gross negligence or willful misconduct of the Indemnified Party seeking indemnification hereunder. The Company also agrees that no Indemnified Party will have any liability (whether direct or
indirect, in contract, tort or otherwise) to the Company or any person asserting claims on behalf of the Company arising out of or in connection with any transactions contemplated by this Agreement or
the engagement of or performance of services by any Indemnified Party thereunder except to the extent that any Damages are found in a final non-appealable judgment by a court of competent jurisdiction
to have resulted from the gross negligence or willful misconduct of the Indemnified Party. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If
for any reason other than in accordance with this Agreement, the foregoing indemnity is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless,
then the Company will contribute to the amount paid or payable by an Indemnified Party as a result of such Damages (including all Expenses incurred) in such proportion as is appropriate to reflect the
relative benefits to the Company and/or its stockholders on the one hand, and the Agents on the other hand, in connection with the matters covered by this Agreement or, if the foregoing allocation is
not permitted by applicable law, not only such relative benefits but also the relative faults of such parties as well as any relevant equitable considerations. The Company agrees that for purposes of
this paragraph the relative benefits to the Company and/or its stockholders and the Agents in connection with the matters covered by this Agreement will be deemed to be in the same proportion that the
total value paid or received or to be paid or received by the Company and/or its stockholders in connection with the transactions contemplated by this Agreement, whether or not consummated, bears to
the fees paid to the Agents under this Agreement; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, that in no event will the total contribution of all Indemnified Parties to all such Damages
exceed the amount of fees actually received and retained by the Agents hereunder (excluding any amounts received by the Agents as reimbursement of expenses). </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
Company agrees not to enter into any waiver, release or settlement of any Proceeding (whether or not the Agent or any other Indemnified Party is a formal party to such Proceeding)
in respect of which indemnification may be sought hereunder without the prior written consent of the Agents (which consent will not be unreasonably withheld), unless such waiver, release or settlement
includes an unconditional release of Agents and each Indemnified Party from all liability arising out of such Proceeding. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The
indemnity, reimbursement and contribution obligations of the Company hereunder will be in addition to any liability which the Company may otherwise have to any Indemnified Party
and will be </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=9,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=362604,FOLIO='10',FILE='DISK032:[01WLA4.01WLA1204]HT1204B.;1',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_11"> </A>
<BR>

<P><FONT SIZE=2>
binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company or an Indemnified Party. The provisions of this Annex will survive the modification,
termination or expiration of this Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=10,SEQ=10,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=984740,FOLIO='11',FILE='DISK032:[01WLA4.01WLA1204]HT1204B.;1',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<A NAME="page_ht1204_1_12"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;The Agents are delighted to accept this engagement and look forward to working with you. Please confirm that the foregoing correctly sets forth our agreement by signing the enclosed
duplicate of this
letter in the space provided and returning it, whereupon this letter shall constitute a binding agreement as of the date first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="79%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Very truly yours,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
CIBC World Markets Corp.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>MICHAEL FEKETE</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Michael Fekete<BR></FONT> <FONT SIZE=2><I>Managing Director</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Adams, Harkness&nbsp;&amp; Hill,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>GREGORY BROWN, M.D.</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Gregory Brown, M.D.<BR></FONT> <FONT SIZE=2><I>Managing Director</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 VALIGN="TOP"><FONT SIZE=2><BR>
ACCEPTED AND AGREED TO<BR>
AS OF THE ABOVE DATE:</FONT></TD>
<TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="TOP"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="TOP"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%" VALIGN="TOP"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
STAAR Surgical Company</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="5%"><FONT SIZE=2><BR>
By:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>ANDREW F. POLLET</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Andrew&nbsp;F. Pollet<BR></FONT> <FONT SIZE=2><I>Chairman<BR> </I></FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><I><BR>&nbsp;</I></FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2><I><BR>
&nbsp;</I></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><I><BR>&nbsp;</I></FONT></TD>
<TD WIDTH="30%"><FONT SIZE=2><I><BR>
&nbsp;</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=11,SEQ=11,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4",CHK=860386,FOLIO='12',FILE='DISK032:[01WLA4.01WLA1204]HT1204B.;1',USER='BKYNARD',CD=';5-MAY-2001;00:25' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01WLA1211_4">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_ht1204_1">Exhibit 10.58</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ht1204_2">ANNEX A</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_ht1204_3">ANNEX B: INDEMNIFICATION</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=DMALONE,SEQ=,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="4" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.77
<SEQUENCE>5
<FILENAME>a2044612zex-10_77.htm
<DESCRIPTION>EX-10-77
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01WLA1211_5">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="hv1204_exhibit_10.77"> </A>
<A NAME="toc_hv1204_1"> </A>
<BR></FONT><FONT SIZE=2><B>EXHIBIT 10.77    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="hv1204_independent_contractor_agreement"> </A>
<A NAME="toc_hv1204_2"> </A></FONT> <FONT SIZE=2><B>INDEPENDENT CONTRACTOR AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>This
Independent Contractor Agreement ("Agreement") is made and effective this January 1<SUP>st</SUP>, 1998 by and between G&uuml;nther Roepstorff, Achtern Felin 20, 25474 Hasloh, Germany
("Consultant") and STAAR Surgical Company, 1911 Walker Ave., Monrovia, CA&nbsp;91016 ("Company"). </FONT></P>

<P><FONT SIZE=2>Now,
therefore, Consultant and Company agree as follows: </FONT></P>

<P><FONT SIZE=2><B>1.&nbsp;&nbsp;Engagement  </B></FONT></P>

<P><FONT SIZE=2>Company
hereby engages Consultant, and Consultant accepts engagement, to provide the Company the following services: </FONT></P>

<P><FONT SIZE=2>Using
the Company's buying power and distribution channels to negotiate prices from manufacturers in the ophthalmic business for products which the company does not currently distribute. Also setting
up distribution for these products where the company is weak or where no distribution currently exist. </FONT></P>


<P><FONT SIZE=2><B>2.&nbsp;&nbsp;Term  </B></FONT></P>

<P><FONT SIZE=2>Consultant
shall provide services to Company pursuant to this agreement for a term commencing on October 1<SUP>st</SUP>, 1999 and ending on October 1<SUP>st</SUP>, 2005. </FONT></P>

<P><FONT SIZE=2><B>3.&nbsp;&nbsp;Place of Work  </B></FONT></P>

<P><FONT SIZE=2>Consultant
shall render services at such locations as at Consultant's deems reasonably necessary, but will, upon request, provide the services at Company offices or such other places as reasonably
requested by Company as appropriate for the performance of particular services. </FONT></P>


<P><FONT SIZE=2><B>4.&nbsp;&nbsp;Time  </B></FONT></P>

<P><FONT SIZE=2>Consultant's
daily schedule and hours worked under this Agreement on a given day shall generally be subject to Consultant's discretion, provided that Consultant and Company anticipate that Consultant
shall work on average ten hours per week in the performance of services pursuant to this Agreement. Company relies upon Consultant to devote sufficient time as is reasonably necessary to fulfill the
spirit and purpose of this Agreement. </FONT></P>

<P><FONT SIZE=2><B>5.&nbsp;&nbsp;Payment  </B></FONT></P>

<P><FONT SIZE=2>Company
shall pay Consultant for services rendered pursuant to this Agreement the sum of US-$20,000&nbsp;&#150;&nbsp;per month. Payments shall be made in US-dollars.
Payments shall be made within 15 days of the last day of each calendar month. </FONT></P>

<P><FONT SIZE=2><B>6.&nbsp;&nbsp;Covenant Not to Compete  </B></FONT></P>

<P><FONT SIZE=2>During
the term of this Agreement and for a period of two years thereafter, Consultant shall not directly or indirectly, either for its own account, or as a partner, shareholder, officer, director,
employee, agent of otherwise, own, manage, operate, control, be employed by, participate in, consult with, perform services for, or otherwise be connected with any business the same as or similar to
the business conducted by Company. In the event any of the provisions of this section&nbsp;6 are determined to be invalid by reason of their scope or duration, this section&nbsp;6 shall be deemed
modified to the extent required to cure the invalidity. In the event of a breach, or a threatened breach, of this section&nbsp;6, Company shall be entitled to obtain an injunction restraining the
commitments or continuance of the breach, as well as any other legal or equitable remedies permitted by law. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="5",CHK=759629,FOLIO='blank',FILE='DISK032:[01WLA4.01WLA1204]HV1204A.;17',USER='DMALONE',CD=';8-MAY-2001;14:21' -->
<A NAME="page_hv1204_1_2"> </A>

<P><FONT SIZE=2><B>7.&nbsp;&nbsp;Confidentiality  </B></FONT></P>

<DL compact>
<DT><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>Consultant
agrees that during the term of Consultant's business relationship with Company, Consultant will have access to and become acquainted with
the confidential proprietary information which is owned by Company and is regularly used in the operation of Company's business. This information includes, but is not limited to, Company's processes,
procedures and know-how, its equipment and inventory, its contracts with vendors, suppliers and other third parties, its permits, licenses and authorizations from governmental or regulatory agencies,
its business records, including but not limited to, customer lists, customer credit information, technical data, including patents, patent applications and other intellectual property, sales data,
correspondence, and its financial information, including, but not limited to, tax returns, financial statements, operating statements, income and expense statements and profit and loss statements and
all notes thereto, all of which information shall be collectively referred to in this Agreement as the "Confidential Information." Confidential Information shall not include any information that
(I)&nbsp;is disclosed by Company without restriction; (II)&nbsp;becomes publicly available through no act of Consultant; (III)&nbsp;is rightfully received by Consultant from a third party.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>Consultant
agrees that all confidential information, whether it is prepared by Consultant or comes into Consultant's possession in any other way,
shall remain the exclusive property of Company.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>Consultant
agrees that Consultant shall not misuse, misappropriate, or disclose in any way to any person or entity any of the confidential
information described herein, either directly or indirectly, nor
will Consultant use the confidential information in any way or at any time, except as required in the course of Consultant's business relationship with Company or if required by law, subpoena or
regulatory process.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2>Consultant
agrees that the sale or unauthorized use or disclosure or any of Company's confidential information which is obtained by Consultant during
Consultant's business relationship with Company constitutes unfair competition. Consultant promises and agrees not to engage in any unfair competition with Company.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(e)</FONT></DT><DD><FONT SIZE=2>Consultant
agrees that, at any time during the term of this Agreement or any extension thereof, upon the request of Company and without further
compensation, but at no expense to Consultant, Consultant shall perform any lawful acts, including the execution of papers and oaths and the giving of testimony, that, in the opinion of Company, its
successors or assigns, may be necessary or desirable in order to obtain, sustain, reissue and renew, and in order to enforce, perfect, record and maintain, patent applications and United States and
foreign patents on Company's inventions, and copyright registrations on Company's inventions.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(f)</FONT></DT><DD><FONT SIZE=2>Consultant's
representations and promises under this section&nbsp;7 shall survive the expiration or termination of this Agreement. </FONT></DD></DL>

<P><FONT SIZE=2><B>8.&nbsp;&nbsp;Termination  </B></FONT></P>

<P><FONT SIZE=2>This
Agreement may be terminated by Company as follows and, upon such termination, Company shall have no further duty or obligation to Consultant pursuant to this Agreement; (I)&nbsp;upon
Consultant's failure to provide the consulting services and such failure is not corrected within 30&nbsp;days after Consultant receives written notice from Company; (II)&nbsp;in the event of
Consultant's dissolution; (III)&nbsp;immediately upon a breach or default of Consultant's obligations pursuant to sections&nbsp;6 and 7 of this Agreement; and (IV)&nbsp;in the event of a breach
or default by Consultant of any other material obligation required to be performed by consultant pursuant to this Agreement, which breach or default is not cured within 30&nbsp;days after Consultant
receives written notice from Company. </FONT></P>


<P><FONT SIZE=2>Also
in the event of an acquisition of an outside company this contract must be fulfilled by the new owner or a one-time payment of the balance till the duration of this contract has to be made. </FONT></P>

<P><FONT SIZE=1>Page&#160;2&#160;of&#160;4&#160;of&#160;the&#160;Independent&#160;Agreement</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="5",CHK=30279,FOLIO='Page 2 of 4 of the Independent Agreement',FILE='DISK032:[01WLA4.01WLA1204]HV1204A.;17',USER='DMALONE',CD=';8-MAY-2001;14:21' -->
<A NAME="page_hv1204_1_3"> </A>
<BR>

<P><FONT SIZE=2><B>9.&nbsp;&nbsp;Independent contractor  </B></FONT></P>

<P><FONT SIZE=2>Consultant
shall not be entitled to nor receive any benefit normally provided to Company's employees such as, but not limited to, vacation payment, retirement, health care or sick pay. Company shall
not be responsible for withholding income or other taxes from the payments made to Consultant. Consultant shall be solely responsible for filing all returns and paying any income, social security or
other tax levied upon or determined with respect to the payments made to Consultant pursuant to this Agreement. </FONT></P>

<P><FONT SIZE=2><B>10.&nbsp;&nbsp;Tools and Supplies  </B></FONT></P>

<P><FONT SIZE=2>Unless
otherwise agreed to by Company in advance, Consultant shall be solely responsible for procuring, paying for and maintaining any computer equipment, software, paper, tools or supplies necessary
or appropriate for the performance of Consultant's services hereunder. </FONT></P>

<P><FONT SIZE=2><B>11.&nbsp;&nbsp;Controlling Law  </B></FONT></P>

<P><FONT SIZE=2>This
Agreement shall be governed by and construed in accordance with the laws of the State of California, USA. </FONT></P>

<P><FONT SIZE=2><B>12.&nbsp;&nbsp;Headings  </B></FONT></P>

<P><FONT SIZE=2>The
headings in this Agreement are inserted for convenience only and shall not be used to define, limit or describe the scope of this Agreement or any of the obligations herein. </FONT></P>


<P><FONT SIZE=2><B>13.&nbsp;&nbsp;Final Agreement  </B></FONT></P>

<P><FONT SIZE=2>This
Agreement constitutes the final understanding and Agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations, understandings and Agreements
between the parties, whether written or oral. This Agreement may be amended, supplemented or changed only by an Agreement in writing signed by both of the parties. </FONT></P>

<P><FONT SIZE=2><B>14.&nbsp;&nbsp;Notices  </B></FONT></P>

<P><FONT SIZE=2>Any
notice required to be given or otherwise given pursuant to this Agreement shall be in writing and shall be hand delivered, mailed by certified mail, return receipt requested or sent by recognized
overnight courier services as follows: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=2><BR>
If to Consultant:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2><BR>
G&uuml;nther Roepstorff<BR>
Achtern Felin 20<BR>
D&#151;25474 Hasloh</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=2><BR>
If to Company:</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2><BR>
STAAR Surgical Company<BR>
1911 Walker Avenue,<BR>
Monrovia, CA 91016</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
<P><FONT SIZE=2><B>15.&nbsp;&nbsp;Severability  </B></FONT></P>

<P><FONT SIZE=2>If
any term of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable, then this Agreement, including all of the remaining terms, will remain in full force and
effect as if such invalid or unenforceable term had never been included. </FONT></P>

<P><FONT SIZE=2><B>16.&nbsp;&nbsp;Arbitration  </B></FONT></P>

<P><FONT SIZE=2>The
parties hereby agree that all controversies, claims and matters of difference relating to this Agreement shall be resolved by binding arbitration before the American Arbitration Association (the </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=1>Page&#160;3&#160;of&#160;4&#160;of&#160;the&#160;Independent&#160;Agreement</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="5",CHK=18630,FOLIO='Page 3 of 4 of the Independent Agreement',FILE='DISK032:[01WLA4.01WLA1204]HV1204A.;17',USER='DMALONE',CD=';8-MAY-2001;14:21' -->
<A NAME="page_hv1204_1_4"> </A>

<P><FONT SIZE=2>
"AAA") located in Los Angeles County, California, according to the rules and practices of the AAA from time to time in force; </FONT><FONT SIZE=2><I>provided, however,</I></FONT><FONT SIZE=2> that
the parties hereto reserve their rights to seek and obtain injunctive or other equitable relief from a court of competent jurisdiction, without waiving the right to compel such arbitration pursuant to
this section. The arbitrator shall apply California law in reaching any decision. </FONT></P>

<P><FONT SIZE=2>IN
WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="46%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>G&Uuml;NTHER ROEPSTORFF</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> G&uuml;nther Roepstorff&nbsp;&nbsp;&nbsp;9.1.98</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="46%"><FONT SIZE=2><BR>
/s/&nbsp;</FONT><FONT SIZE=2>WILLIAM C. HUDDLESTON</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> STAAR Surgical Company<BR>
by William C. Huddleston<BR></FONT>
</TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=1>Page&#160;4&#160;of&#160;4&#160;of&#160;the&#160;Independent&#160;Agreement</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="5",CHK=252546,FOLIO='Page 4 of 4 of the Independent Agreement',FILE='DISK032:[01WLA4.01WLA1204]HV1204A.;17',USER='DMALONE',CD=';8-MAY-2001;14:21' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01WLA1211_5">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_hv1204_1">EXHIBIT 10.77</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_hv1204_2">INDEPENDENT CONTRACTOR AGREEMENT</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DMALONE,SEQ=,EFW="2044612",CP="STAAR SURGICAL COMPANY",DN="5" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
